Predictive Oncology (POAI) 10-K 1 Apr 20 2019 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2019	Mar. 27, 2020	Jun. 30, 2019
Document Information [Line Items]
Entity Registrant Name	Predictive Oncology Inc.
Entity Central Index Key	0001446159
Trading Symbol	poai
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Interactive Data Current	Yes
Entity Common Stock, Shares Outstanding (in shares)		5,847,718
Entity Public Float			$ 19,734,292
Entity Shell Company	false
Document Type	10-K
Document Period End Date	Dec. 31, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	FY
Amendment Flag	false
Title of 12(b) Security	Common Stock, $0.01 par value

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Current Assets:
Cash and Cash Equivalents	$ 150,831	$ 162,152
Accounts Receivable	297,055	232,602
Notes Receivable (inclusive of $0 and $452,775 in advances to Helomics; net of $1,037,524 and $0 in allowances for credit losses)		497,276
Inventories	190,156	241,066
Prepaid Expense and Other Assets	160,222	318,431
Total Current Assets	798,264	1,451,527
Notes Receivable		1,112,524
Fixed Assets, net	1,507,799	180,453
Intangibles, net	3,649,412	964,495
Lease Right-of-Use Assets	729,745
Goodwill	15,690,290
Total Assets	22,375,510	3,708,999
LIABILITIES AND STOCKHOLDERS' EQUITY
Accounts Payable	3,155,641	445,689
Notes Payable – Net of Discounts of $350,426 and $1,032,813	4,795,800	1,634,914
Accrued Expenses	2,371,633	1,279,114
Derivative Liability	50,989	272,745
Deferred Revenue	40,384	23,065
Lease Liability – Net of Long-Term Portion	459,481
Total Current Liabilities	10,873,928	3,655,527
Lease Liability	270,264
Total Liabilities	11,144,192	3,655,527
Stockholders’ Equity:
Common Stock, $.01 par value, 100,000,000 and 50,000,000 authorized, 4,056,652 and 1,409,175 outstanding	40,567	14,092
Additional Paid-in Capital	93,653,667	63,146,533
Accumulated Deficit	(82,498,711)	(63,107,945)
Total Stockholders' Equity	11,231,318	53,472
Total Liabilities and Stockholders' Equity	22,375,510	3,708,999
Series B Convertible Preferred Stock [Member]
Stockholders’ Equity:
Convertible Preferred Stock	792	792
Series D Convertible Preferred Stock [Member]
Stockholders’ Equity:
Convertible Preferred Stock	35,000
Series E Convertible Preferred Stock [Member]
Stockholders’ Equity:
Convertible Preferred Stock	$ 3

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Notes receivable		$ 497,276
Reserve for bad debt	1,037,524	0
Discount of note payable	$ 350,426	$ 1,032,814
Preferred stock, shares authorized (in shares)	20,000,000	20,000,000
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	100,000,000	50,000,000
Common stock, shares outstanding (in shares)	4,056,652	1,409,175
Series B Convertible Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	2,300,000	2,300,000
Preferred stock, shares outstanding (in shares)	79,246	79,246
Series D Convertible Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	3,500,000	3,500,000
Preferred stock, shares outstanding (in shares)	3,500,000	0
Series E Convertible Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	350	350
Preferred stock, shares outstanding (in shares)	257.258	0
Helomics Holding [Member]
Notes receivable	$ 0	$ 452,775

Consolidated Statements of Net

Consolidated Statements of Net Loss - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Revenue	$ 1,411,565	$ 1,411,655
Cost of goods sold	531,810	415,764
Gross margin	879,755	995,891
General and administrative expense	9,781,218	4,626,997
Operations expense	2,960,131	1,861,121
Sales and marketing expense	1,912,899	2,369,152
Total operating loss	(13,774,493)	(7,861,379)
Gain on revaluation of cash advances to Helomics	1,222,244
Other income	287,056	510,254
Other expense	(3,979,946)	(441,772)
Impairment	(8,100,000)	0
Loss on intangible impairment	(770,250)
Loss on equity method investment	(439,637)	(2,293,580)
Gain on revaluation of equity method investment	6,164,260
Net loss	(19,390,766)	(10,086,477)
Deemed dividend on Series E Convertible Preferred Stock	289,935
Net loss attributable to common shareholders	$ (19,680,701)	$ (10,086,477)
Loss per common share - basic and diluted (in dollars per share)	$ (6.86)	$ (7.87)
Weighted average shares used in computation - basic and diluted (in shares)	2,870,132	1,281,629

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($)	Preferred Stock [Member]Series B Convertible Preferred Stock [Member]Chief Executive Officer [Member]	Preferred Stock [Member]Series B Convertible Preferred Stock [Member]Helomics Holding Corp. [Member]	Preferred Stock [Member]Series B Convertible Preferred Stock [Member]Private Placement [Member]	Preferred Stock [Member]Series B Convertible Preferred Stock [Member]Over-Allotment Option [Member]	Preferred Stock [Member]Series B Convertible Preferred Stock [Member]Equity Line Purchase Agreement [Member]	Preferred Stock [Member]Series B Convertible Preferred Stock [Member]Series E Warrants [Member]	Preferred Stock [Member]Series B Convertible Preferred Stock [Member]Re-priced Warrants [Member]	Preferred Stock [Member]Series B Convertible Preferred Stock [Member]Warrants Issued With Promissory Note [Member]	Preferred Stock [Member]Series B Convertible Preferred Stock [Member]Warrants Issued to CEO [Member]	Preferred Stock [Member]Series B Convertible Preferred Stock [Member]Bridge Loan Warrants [Member]	Preferred Stock [Member]Series B Convertible Preferred Stock [Member]Warrants Issued to Helomics' Investors [Member]	Preferred Stock [Member]Series B Convertible Preferred Stock [Member]Note Payable Warrants [Member]	Preferred Stock [Member]Series B Convertible Preferred Stock [Member]Warrants Held by Noteholders [Member]	Preferred Stock [Member]Series B Convertible Preferred Stock [Member]Bridge Notes [Member]	Preferred Stock [Member]Series B Convertible Preferred Stock [Member]Bridge Loan Agreement [Member]	Preferred Stock [Member]Series B Convertible Preferred Stock [Member]Promissory Note [Member]	Preferred Stock [Member]Series B Convertible Preferred Stock [Member]Consulting Agreement One [Member]	Preferred Stock [Member]Series B Convertible Preferred Stock [Member]Contract with TumorGenesis [Member]	Preferred Stock [Member]Series B Convertible Preferred Stock [Member]Investor Relations Consultant [Member]	Preferred Stock [Member]Series B Convertible Preferred Stock [Member]Converison of Bridge Loan to Common Stock [Member]	Preferred Stock [Member]Series B Convertible Preferred Stock [Member]	Preferred Stock [Member]Series D Convertible Preferred Stock [Member]Chief Executive Officer [Member]	Preferred Stock [Member]Series D Convertible Preferred Stock [Member]Private Placement [Member]	Preferred Stock [Member]Series D Convertible Preferred Stock [Member]Equity Line Purchase Agreement [Member]	Preferred Stock [Member]Series D Convertible Preferred Stock [Member]Warrants Issued With Promissory Note [Member]	Preferred Stock [Member]Series D Convertible Preferred Stock [Member]Warrants Issued to CEO [Member]	Preferred Stock [Member]Series D Convertible Preferred Stock [Member]Warrants Issued to Helomics' Investors [Member]	Preferred Stock [Member]Series D Convertible Preferred Stock [Member]Warrants Held by Noteholders [Member]	Preferred Stock [Member]Series D Convertible Preferred Stock [Member]Bridge Notes [Member]	Preferred Stock [Member]Series D Convertible Preferred Stock [Member]Bridge Loan Agreement [Member]	Preferred Stock [Member]Series D Convertible Preferred Stock [Member]Promissory Note [Member]	Preferred Stock [Member]Series D Convertible Preferred Stock [Member]Investor Relations Consultant [Member]	Preferred Stock [Member]Series D Convertible Preferred Stock [Member]	Preferred Stock [Member]Series E Convertible Preferred Stock [Member]Chief Executive Officer [Member]	Preferred Stock [Member]Series E Convertible Preferred Stock [Member]Private Placement [Member]	Preferred Stock [Member]Series E Convertible Preferred Stock [Member]Equity Line Purchase Agreement [Member]	Preferred Stock [Member]Series E Convertible Preferred Stock [Member]Warrants Issued With Promissory Note [Member]	Preferred Stock [Member]Series E Convertible Preferred Stock [Member]Warrants Issued to CEO [Member]	Preferred Stock [Member]Series E Convertible Preferred Stock [Member]Warrants Issued to Helomics' Investors [Member]	Preferred Stock [Member]Series E Convertible Preferred Stock [Member]Warrants Held by Noteholders [Member]	Preferred Stock [Member]Series E Convertible Preferred Stock [Member]Bridge Notes [Member]	Preferred Stock [Member]Series E Convertible Preferred Stock [Member]Bridge Loan Agreement [Member]	Preferred Stock [Member]Series E Convertible Preferred Stock [Member]Promissory Note [Member]	Preferred Stock [Member]Series E Convertible Preferred Stock [Member]Investor Relations Consultant [Member]	Preferred Stock [Member]Series E Convertible Preferred Stock [Member]	Preferred Stock [Member]Series C Convertible Preferred Stock [Member]Helomics Holding Corp. [Member]	Preferred Stock [Member]Series C Convertible Preferred Stock [Member]Over-Allotment Option [Member]	Preferred Stock [Member]Series C Convertible Preferred Stock [Member]Series E Warrants [Member]	Preferred Stock [Member]Series C Convertible Preferred Stock [Member]Re-priced Warrants [Member]	Preferred Stock [Member]Series C Convertible Preferred Stock [Member]Bridge Loan Warrants [Member]	Preferred Stock [Member]Series C Convertible Preferred Stock [Member]Note Payable Warrants [Member]	Preferred Stock [Member]Series C Convertible Preferred Stock [Member]Consulting Agreement One [Member]	Preferred Stock [Member]Series C Convertible Preferred Stock [Member]Contract with TumorGenesis [Member]	Preferred Stock [Member]Series C Convertible Preferred Stock [Member]Converison of Bridge Loan to Common Stock [Member]	Preferred Stock [Member]Series C Convertible Preferred Stock [Member]	Common Stock [Member]Chief Executive Officer [Member]	Common Stock [Member]Helomics Holding Corp. [Member]	Common Stock [Member]Private Placement [Member]	Common Stock [Member]Over-Allotment Option [Member]	Common Stock [Member]Equity Line Purchase Agreement [Member]	Common Stock [Member]Series E Warrants [Member]	Common Stock [Member]Re-priced Warrants [Member]	Common Stock [Member]Warrants Issued With Promissory Note [Member]	Common Stock [Member]Warrants Issued to CEO [Member]	Common Stock [Member]Bridge Loan Warrants [Member]	Common Stock [Member]Warrants Issued to Helomics' Investors [Member]	Common Stock [Member]Note Payable Warrants [Member]	Common Stock [Member]Warrants Held by Noteholders [Member]	Common Stock [Member]Bridge Notes [Member]	Common Stock [Member]Bridge Loan Agreement [Member]	Common Stock [Member]Promissory Note [Member]	Common Stock [Member]Consulting Agreement One [Member]	Common Stock [Member]Contract with TumorGenesis [Member]	Common Stock [Member]Investor Relations Consultant [Member]	Common Stock [Member]Converison of Bridge Loan to Common Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]Chief Executive Officer [Member]	Additional Paid-in Capital [Member]Helomics Holding Corp. [Member]	Additional Paid-in Capital [Member]Private Placement [Member]	Additional Paid-in Capital [Member]Over-Allotment Option [Member]	Additional Paid-in Capital [Member]Equity Line Purchase Agreement [Member]	Additional Paid-in Capital [Member]Series E Warrants [Member]	Additional Paid-in Capital [Member]Re-priced Warrants [Member]	Additional Paid-in Capital [Member]Warrants Issued With Promissory Note [Member]	Additional Paid-in Capital [Member]Warrants Issued to CEO [Member]	Additional Paid-in Capital [Member]Bridge Loan Warrants [Member]	Additional Paid-in Capital [Member]Warrants Issued to Helomics' Investors [Member]	Additional Paid-in Capital [Member]Note Payable Warrants [Member]	Additional Paid-in Capital [Member]Warrants Held by Noteholders [Member]	Additional Paid-in Capital [Member]Bridge Notes [Member]	Additional Paid-in Capital [Member]Bridge Loan Agreement [Member]	Additional Paid-in Capital [Member]Promissory Note [Member]	Additional Paid-in Capital [Member]Consulting Agreement One [Member]	Additional Paid-in Capital [Member]Contract with TumorGenesis [Member]	Additional Paid-in Capital [Member]Investor Relations Consultant [Member]	Additional Paid-in Capital [Member]Converison of Bridge Loan to Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]Chief Executive Officer [Member]	Retained Earnings [Member]Helomics Holding Corp. [Member]	Retained Earnings [Member]Private Placement [Member]	Retained Earnings [Member]Over-Allotment Option [Member]	Retained Earnings [Member]Equity Line Purchase Agreement [Member]	Retained Earnings [Member]Series E Warrants [Member]	Retained Earnings [Member]Re-priced Warrants [Member]	Retained Earnings [Member]Warrants Issued With Promissory Note [Member]	Retained Earnings [Member]Warrants Issued to CEO [Member]	Retained Earnings [Member]Bridge Loan Warrants [Member]	Retained Earnings [Member]Warrants Issued to Helomics' Investors [Member]	Retained Earnings [Member]Note Payable Warrants [Member]	Retained Earnings [Member]Warrants Held by Noteholders [Member]	Retained Earnings [Member]Bridge Notes [Member]	Retained Earnings [Member]Bridge Loan Agreement [Member]	Retained Earnings [Member]Promissory Note [Member]	Retained Earnings [Member]Consulting Agreement One [Member]	Retained Earnings [Member]Contract with TumorGenesis [Member]	Retained Earnings [Member]Investor Relations Consultant [Member]	Retained Earnings [Member]Converison of Bridge Loan to Common Stock [Member]	Retained Earnings [Member]	Chief Executive Officer [Member]	Helomics Holding Corp. [Member]	Private Placement [Member]	Over-Allotment Option [Member]	Equity Line Purchase Agreement [Member]	Series E Warrants [Member]	Re-priced Warrants [Member]	Warrants Issued With Promissory Note [Member]	Warrants Issued to CEO [Member]	Bridge Loan Warrants [Member]	Warrants Issued to Helomics' Investors [Member]	Note Payable Warrants [Member]	Warrants Held by Noteholders [Member]	Bridge Notes [Member]	Bridge Loan Agreement [Member]	Promissory Note [Member]	Consulting Agreement One [Member]	Contract with TumorGenesis [Member]	Investor Relations Consultant [Member]	Converison of Bridge Loan to Common Stock [Member]	Total
Balance (in shares) at Dec. 31, 2017																					79,246																																		647,819																					694,328
Balance at Dec. 31, 2017																					$ 792																																		$ 6,479																					$ 6,943																					$ 55,699,169																					$ (53,021,469)																					$ 2,691,914
Preferred conversion to common shares pursuant to private placement agreement (in shares)																																																							(647,819)
Preferred conversion to common shares pursuant to private placement agreement																																																							$ (6,479)																																																																																				(6,479)
Preferred conversion to common shares pursuant to private placement agreement (in shares)																																																																											65,000	58,975
Preferred conversion to common shares pursuant to private placement agreement																																																																											$ 650	$ 590																				$ 205,955	5,889																																									$ 206,605
Shares issued (in shares)																																																											21,525																	290,000
Shares issued																																																											$ 215																	$ 2,900				$ 204,206																	2,752,187				$ 1																					$ 204,422																	2,755,087
Investment in Subsidiary pursuant to Helomics 20% acquisition (in shares)																																																									110,000
Investment in Subsidiary pursuant to Helomics 20% acquisition																																																									$ 1,100																					$ 1,041,150																																										$ 1,042,250
Warrant exercises (in shares)																																																													14,539	50,467
Warrant exercises																																																													$ 145	$ 505																				$ 145,251	$ 504,160																																									$ 145,396	$ 504,665
Shares issued pursuant to a consultant contract @ 11.80 per share (in shares)																																																																								25,000
Shares issued pursuant to a consultant contract @ 11.80 per share																																																																								$ 250																					$ 294,750																																										$ 295,000
Shares issued in escrow pursuant to a contract with TumorGenesis @ 11.70 per share (in shares)																																																																									75,000
Shares issued in escrow pursuant to a contract with TumorGenesis @ 11.70 per share																																																																									$ 750																					$ 876,750																																										$ 877,500
Warrants issued																																																																																						$ 183,187		$ 68,757																																								$ 183,187		$ 68,757
Shares issued to employee in lieu of bonus (in shares)																																																																												4,341
Shares issued to employee in lieu of bonus																																																																												$ 44																					40,194																																										40,238
Vesting Expense																																																																																																	1,124,928																																										1,124,928
Net loss																																																																																																																						(10,086,477)																					(10,086,477)
Balance (in shares) at Dec. 31, 2018																					79,246																																																							1,409,175
Balance at Dec. 31, 2018																					$ 792																																																							$ 14,092																					63,146,533																					(63,107,945)																					53,472
Preferred conversion to common shares pursuant to private placement agreement
Preferred conversion to common shares pursuant to private placement agreement (in shares)																																																																					103,415	30,000	8,857
Preferred conversion to common shares pursuant to private placement agreement																																																																					$ 1,034	$ 300	$ 89																			$ 377,539	$ 127,200	$ 130,129																																								$ 378,573	$ 127,500	$ 130,218
Shares issued (in shares)																																																								7,813		919,929		122,356																																																															122,356
Shares issued																																																								$ 78		$ 9,200		$ 1,224																	$ 49,922		$ 5,263,818		$ 317,972																																						$ 50,000		$ 5,273,018		$ 319,196
Investment in Subsidiary pursuant to Helomics 20% acquisition (in shares)																																	3,500,000																																											400,000
Investment in Subsidiary pursuant to Helomics 20% acquisition																																	$ 35,000																																											$ 4,000																					5,573,250																																										5,612,250
Warrant exercises (in shares)																																																																												59,700
Warrant exercises																																																																												$ 597																					5,373																																										5,970
Shares issued pursuant to a consultant contract @ 11.80 per share (in shares)																																																																										10,356
Shares issued pursuant to a consultant contract @ 11.80 per share																																																																										$ 103																					$ 34,820																																										$ 34,923
Warrants issued																																																																																				$ 180,640	$ 356,471		$ 6,261,590		$ 177,343																																					$ 180,640	$ 356,471		$ 6,261,590		$ 177,343
Vesting Expense																																																																																																	2,250,422																																										2,250,422
Net loss																																																																																																																						(19,390,766)																					(19,390,766)
Shares issued in forbearance agreement (in shares)																																																																												16,667
Shares issued in forbearance agreement																																																																												$ 166																					158,183																																										158,349
Stock issued to extinguish debt as part of Helomics purchase consideration (in shares)																																																																												863,732
Value of shares to extinguish debt (iii)																																																																												$ 8,637																					6,454,672																																										6,463,309
Issuance of Series E preferred shares (in shares)																																													258
Issuance of Series E preferred shares																																													$ 3																																																				2,338,837																																										2,338,840
Inducement shares issued pursuant to equity line (in shares)																																																																												104,652
Inducement shares issued pursuant to equity line																																																																												$ 1,047																					448,953																																										450,000
Balance (in shares) at Dec. 31, 2019																					79,246												3,500,000												258																															4,056,652
Balance at Dec. 31, 2019																					$ 792												$ 35,000												$ 3																															$ 40,567																					$ 93,653,667																					$ (82,498,711)																					$ 11,231,318

Consolidated Statements of St_2

Consolidated Statements of Stockholders' Equity (Parentheticals)	Dec. 31, 2018$ / shares
Consulting Agreement One [Member]
Price of shares issued (in dollars per share)	$ 11.80
Contract with TumorGenesis [Member]
Price of shares issued (in dollars per share)	11.70
Over-Allotment Option [Member]
Price of shares issued (in dollars per share)	9.497
Series E Warrants [Member]
Warrant exercises, exercise price per share (in dollars per share)	$ 10

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Cash flow from operating activities:
Net loss	$ (19,390,766)	$ (10,086,477)
Adjustments to reconcile net loss to net cash used in operating activities:
Recognition of credit loss on notes receivable	1,037,524
Loss on equity method investment	439,637	2,293,580
Gain on revaluation of equity method investment	(6,164,260)
Depreciation and amortization	704,883	147,628
Vesting expense	2,250,422	1,124,928
Equity instruments issued for management, consulting, and other	484,923	335,238
Amortization of debt discount	2,023,315	385,111
Gain on valuation of equity-linked instruments	(221,756)	(372,263)
Gain on revaluation of cash advances to Helomics	(1,222,244)
Debt extinguishment costs	581,073
Loss on goodwill and intangible impairment	8,870,250
Loss on fixed asset disposal	1,096
Changes in assets and liabilities:
Accounts receivable	143,316	(95,103)
Inventories	91,114	23,979
Prepaid expense and other assets	(29,747)	139,895
Accounts payable	365,772	305,227
Accrued expenses	1,285,678	493,899
Deferred revenue	17,319	16,402
Net cash used in operating activities	(8,732,451)	(5,287,956)
Cash flow from investing activities:
Redemption of certificates of deposit		244,971
Advances on notes receivable	(975,000)	(1,123,619)
Cash received from notes receivable	154,418
Cash received from Helomics acquisition	248,102
Purchase of fixed assets	(5,888)	(177,732)
Acquisition of intangibles	(20,719)	(54,271)
Net cash used in investing activities	(599,087)	(1,110,651)
Cash flow from financing activities:
Proceeds from debt issuance	2,690,000	2,185,000
Repayment of debt	(1,154,513)
Payment penalties	(202,294)
Proceeds from issuance of stock pursuant to equity line	319,196
Proceeds from exercise of warrants into common stock	5,970	650,061
Proceeds from issuance of Series E convertible preferred stock	2,338,840
Issuance of common stock	5,323,018	2,959,509
Net cash provided by financing activities	9,320,217	5,794,570
Net decrease in cash	(11,321)	(604,037)
Cash at beginning of period	162,152	766,189
Cash at end of period	150,831	162,152
Non-cash transactions
Bridge loan conversion into common stock	378,573
Forbearance settlement bridge loan	503,009
Warrants Issued	47,078
Warrants issued pursuant to debt issuance	180,640
Consideration given for acquisition of Helomics	26,711,790
Debt modification costs	162,750
Conversion of preferred stock to common stock		6,479
Equity method investment – Helomics		1,542,250
Licensing fee for TumorGenesis		877,500
Interest paid on debt	$ 146,064

Note 1 - Summary of Significant

Note 1 - Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Significant Accounting Policies [Text Block]	NOTE 1 Nature of Operations and Continuance of Operations Predictive Oncology Inc., (the “Company” or “Predictive”) was originally incorporated on April 23, 2002 August 6, 2013, December 16, 2013, August 31, 2015, February 1, 2018, February 1, 2018. February 2, 2018. June 10, 2019, June 13, 2019. October 28, 2019, one ten October 29, 2019. The Company is a healthcare company that provides personalized medicine solution and medical devices in two 1 2 In addition, the Company’s wholly-owned subsidiary, TumorGenesis Inc. (“TumorGenesis”), is developing the next generation, patient-derived tumor models for precision cancer therapy and drug development. TumorGenesis Inc., formed during the first 2018, During the first 2018, 25% April 4, 2019, 75% The Company has incurred recurring losses from operations and has an accumulated deficit of $82,498,711. not 2019, no may $150,831 December 31, 2019 $6,213,507 December 31, 2019, six may October 2019, $15,000,000 three no three 2019, 122,356 $319,196 2020, $6,159,906, 13 not one not The Company has no Recently Adopted Accounting Standards In February 2016, No. 2016 02, Leases (Topic 842 2016 02” December 15, 2018. 2016 02 January 1, 2019, $353,007 $79,252 2016 02 not The Company leases facilities under long-term operating leases that are non-cancelable and expire on various dates. At the lease commencement date, lease ROU assets and lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term, which includes all fixed obligations arising from the lease contract. If an interest rate is not 10 Accounting Policies and Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and disclosure of contingent assets and liabilities at the date of the financial statements and during the reporting period. Actual results could materially differ from those estimates. Cash and Cash Equivalents Cash and cash equivalents consist of cash on hand. The company has no December 31, 2018 December 31, 2019. Receivables Receivables are reported at the amount the Company expects to collect on balances outstanding. The Company provides for probable uncollectible amounts through charges to earnings and credits to the valuation allowance based on management’s assessment of the current status of individual accounts. During 2019, $1,037,524 6 Inventories Inventories are stated at the lower of cost or net realizable value, with cost determined on a first first December 31, December 31, Finished goods $ 91,410 $ 58,701 Raw materials 69,821 127,003 Work-In-Process 28,925 55,362 Total $ 190,156 $ 241,066 Fixed Assets Fixed assets are stated at cost less accumulated depreciation. Depreciation of fixed assets is computed using the straight-line method over the estimated useful lives of the respective assets. Accumulated depreciation is included in fixed assets, net on the accompanying consolidated balance sheets. Estimated useful life by asset classification is as follows: Years Computers and office equipment 3 - 7 Leasehold improvements (1) 5 Manufacturing and laboratory equipment 3 - 7 Demonstration equipment 3 Laboratory equipment 4 ( 1 Leasehold improvements are depreciated over the shorter of the useful life or the remaining lease term. The Company’s fixed assets consist of the following: December 31, December 31, Computers and office equipment $ 508,143 $ 204,903 Leasehold improvements 188,014 140,114 Manufacturing tooling 1,510,165 108,955 Demo equipment 73,051 85,246 Total 2,279,373 539,218 Less: Accumulated depreciation 771,574 358,765 Total fixed assets, net $ 1,507,799 $ 180,453 Upon retirement or sale or fixed assets, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is reflected in operations expense. Maintenance and repairs are expensed as incurred. Depreciation expense was $414,331 $84,995 2019 2018, Intangible Assets Finite-lived intangible assets consist of patents and trademarks, licensing fees, developed technology, and customer relationships, and are amortized over their estimated useful life. The tradename is an indefinite-lived intangible asset and is not $290,552 $62,633 2019 2018, 360 Property, Plant and Equipment may not may not not 350— Intangibles—Goodwill and Other not As of December 31, 2019, $3,649,412 $964,495 December 31, 2018. The components of intangible assets were as follows: December 31, 2019 December 31, 2018 Gross Accumulated Net Carrying Gross Accumulated Net Carrying Patents & Trademarks $ 339,023 $ (195,286 ) $ 143,737 $ 318,304 $ (182,559 ) $ 135,745 Licensing Fees - - - 877,500 (48,750 ) 828,750 Developed Technology 2,882,000 (108,075 ) 2,773,925 - - - Customer Relationships 445,000 (111,250 ) 333,750 - - - Tradename 398,000 - 398,000 - - - Total $ 4,064,023 $ (414,611 ) $ 3,649,412 $ 1,195,804 $ (231,309 ) $ 964,495 The following table outlines the estimated future amortization expense related to intangible assets held as of December 31, 2019: Year ending December 31, Expense 2020 $ 305,785 2021 305,785 2022 194,535 2023 157,452 2024 157,452 Thereafter 2,130,403 Total $ 3,251,412 Impairment of Long-Lived Assets The Company reviews long-lived assets, including property and equipment and intangible assets with estimable useful lives, for impairment whenever events or changes in circumstances indicate that the carrying amount of such an asset may not The recoverability of an asset to be held and used is determined by comparing the carrying amount to the estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of the asset exceeded its estimated undiscounted future cash flows, the Company recorded an impairment charge in the amount by which the carrying amount of the asset exceeds its fair value, which is determined by either a quoted market price, if any, or a value determined by utilizing discounted cash flow techniques. During 2019, $58,500 may not $770,250 No 2018. Goodwill In accordance with ASC 350 Intangibles – Goodwill and Other not In the Helomics acquisition, the Company recorded goodwill of $23,790,290. not not first may In testing goodwill for impairment as of December 31, 2019, December 31, 2019. 2017 04 Simplifying the Test for Goodwill Impairment December 31, 2019 $8,100,000 no twelve December 31, 2018. Goodwill balance at December 31, 2018 $ - Acquired 23,790,290 Impairment (8,100,000 ) Goodwill balance at December 31, 2019 $ 15,690,290 When evaluating the fair value of Helomics reporting unit the Company used a discounted cash flow model. Key assumptions used to determine the estimated fair value included: (a) expected cash flow for the 20 3.0% 18.3% 7% The majority of the inputs used in the discounted cash flow model are unobservable and thus are considered to be Level 3 The Company will continue to monitor its reporting units to determine whether events and circumstances warrant further interim impairment testing. Goodwill is not Fair Value Measurements As outlined in ASC – 820, Fair Value Measurement 820 three Level 1 Level 2 Level 3 no The Company uses observable market data, when available, in making fair value measurements. Fair value measurements are classified according to the lowest level input that is significant to the valuation. The fair value of the Company’s investment securities, which consist of cash and cash equivalents, was determined based on Level 1 3 Revenue Recognition The Company recognizes revenue when it satisfies a performance obligation by transferring control of the promised goods or services to its customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. Sales taxes are imposed on the Company’s sales to nonexempt customers. The Company collects the taxes from the customers and remits the entire amounts to the governmental authorities. Sales taxes are excluded from revenue and expenses. See Note 4 Income Taxes The Company accounts for income taxes in accordance with ASC 740 Income Taxes 740” 740, There is no 100% The Company reviews income tax positions expected to be taken in income tax returns to determine if there are any income tax uncertainties. The Company recognizes tax benefits from uncertain tax positions only if it is more likely than not no Under Internal Revenue Code Section 382, may not not 382 may 382 2020. Tax years subsequent to 2015 Advertising Advertising costs are expensed as incurred. Advertising expenses were $21,166 2019 $43,548 2018. Research and Development Research and development costs are charged to operations as incurred. Research and development costs were $422,964 $526,257 2019 2018, Offering Costs Costs incurred which are direct and incremental to an offering of the Company’s securities are deferred and charged against the proceeds of the offering, unless such costs are deemed to be insignificant in which case they are expensed as incurred. During 2019, $324,459 Credit Risk Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash. The Company places its cash with high credit quality financial institutions and, by policy, generally limits the amount of credit exposure to any one no Product Warranty Costs In 2019 2018, $15,717 $10,682, Other Expense Other expense consisted primarily of interest expense, payment penalties, amortization of original issue discounts, and loss on debt extinguishment associated to the Company’s notes payable. Segments The Company has determined its operating segments in accordance with ASC 280 Segment Reporting During the fourth 2019, one not 2018, three 4 December 31, 2019 2 not Year Ended December 31, 2019 Domestic International Helomics Corporate Total Revenue $ 1,275,048 $ 88,070 $ 48,447 - $ 1,411,565 Depreciation and Amortization (43,728 ) (4,692 ) (556,538 ) (99,925 ) (704,883 ) Impairment expense - - (8,100,000 ) (770,250 ) (8,870,250 ) Loss on equity method investment - - - (439,637 ) (439,637 ) Segment Loss $ (2,783,531 ) $ (351,759 ) $ (12,354,108 ) $ (3,901,368 ) $ (19,390,766 ) December 31, 2019 Domestic International Helomics Corporate Total Assets $ 670,841 $ 298,952 $ 21,275,306 $ 130,411 $ 22,375,510 In 2018, December 31, 2018 Domestic International Helomics Corporate Total Assets $ 932,367 $ 41,377 - $ 2,735,255 $ 3,708,999 Risks and Uncertainties The Company is subject to risks common to companies in the medical device and biopharmaceutical industries, including, but not

Note 2 - Helomics Acquisition

Note 2 - Helomics Acquisition	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Business Combination Disclosure [Text Block]	NOTE 2 On April 4, 2019, 75% Helomics’ precision medicine services are designed to use AI and a comprehensive disease database to improve the effectiveness of cancer therapy. Helomics’ precision oncology services are based on its D-CHIP diagnostic platform, which combines a database of genomic and drug response profiles from over 149,000 The acquisition of Helomics was accounted for as a business combination using the acquisition method of accounting. This method requires, among other things, that assets acquired and liabilities assumed be recognized at fair value as of the acquisition date. The fair value for the assets acquired and the liabilities assumed are based on information knowable and determined by management as of the date of this filing. The Company incurred $656,615 The fair value of the consideration transferred in the acquisition has five $26,711,790. Value of shares to Helomics shareholders (i) $ 5,612,250 Value of Helomics notes receivable forgiven (ii) 2,210,381 Value of shares to extinguish debt (iii) 6,463,309 Value of warrants issued (iv) 6,261,590 Gain on revaluation of equity method investment (v) 6,164,260 Fair value of the consideration $ 26,711,790 Less assets acquired: Cash and cash equivalents 248,102 Accounts receivable 207,769 Inventory 17,727 Prepaid expenses 15,321 Fixed assets, net 1,749,080 Intangible assets 3,725,000 Lease right of use assets 780,594 Plus liabilities assumed: Accounts payable 2,374,596 Note Payable 303,333 Accrued expenses 363,569 Lease Liability – Net of Long-term Portion 422,126 Lease liability 358,468 Total assets acquired and liabilities assumed (2,921,501 ) Goodwill $ 23,790,290 (i) Upon the acquisition, all outstanding shares of Helomics stock not 400,000 3,500,000 $5,612,250; $2,210,381; 863,732 $6,463,309; 1,425,506 23,741,772 59,700 $6,261,590; 25% 2018 $6,164,260 75% 10% The fair values of all common and preferred shares issued as consideration in the transaction was determined using the closing bid price of the Company’s common stock on April 4, 2019. The Company did not three not $303,333 October 11, 2019. fourth 2019. 58,300 $1.00 7 Identifiable Intangible Assets The Company acquired intangible assets related to trademarks for the acquired Helomics trade name with an estimated fair market value of $398,000. The Company acquired intangible assets with a useful life of three $445,000 The Company acquired intangible assets with a useful life of 20 $2,882,000 The acquisition costs related to the intangible assets are presented in legal and accounting expenses within general and administrative expenses in the accompanying consolidated statements of net loss. Goodwill Goodwill of $23,790,290 None Financial Results The financial results of Helomics since the acquisition date have been included in the Company’s accompanying consolidated statements of net loss. Pro Forma The following pro forma information presents the combined results of operations of the Company and Helomics as if the acquisition of Helomics had been completed on January 1, 2018, Year Ended December 31, 2019 2018 Unaudited Revenue $ 1,457,625 $ 1,812,433 Net loss attributable to common shareholders $ (20,947,033 ) (12,419,423 ) The primary adjustments include the deduction of the original depreciation and amortization and the inclusion of the revalued depreciation and amortization for Helomics tangible and intangible assets. The unaudited pro forma results do not may not There are certain portions of purchase accounting, specifically Section 382 Tax Loss Carryforwards not may

Note 3 - Equity Method Investme

Note 3 - Equity Method Investment	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Equity Method Investments and Joint Ventures Disclosure [Text Block]	NOTE 3 The Company acquired 25% first 2018. April 4, 2019, zero $439,637 $2,293,580 2019 2018, Summarized financial information for Helomics for the year ended December 31, 2019 not December 31, 2018 December 31, 2018 Current assets $ 419,266 Non-current assets 2,046,347 Total assets 2,465,613 Current liabilities 12,247,174 Total liabilities 12,247,174 Period January 1, 2019 to April 4, 2019 Year Ended December 31, 2018 Revenue $ 45,835 $ 523,546 Gross margin 7,348 214,426 Net loss on Operations (1,555,542 ) (9,452,835 ) Net Loss (1,166,656 ) 1 (7,159,255 ) 1 1 80% January 11, 2018 – February 27, 2018, 75% February 28, 2018 – April 4, 2019 The Helomics losses reduced the equity method investment asset on the balance sheet. The recorded investor losses have exceeded the equity method investment originally recorded total. As such, the equity method investment recorded to the balance sheet was reduced to zero. Subsequent losses reduced the note receivable due from Helomics. Note receivable on the balance sheet as of December 31, 2018 $413,683. $1,165,013 $751,330

Note 4 - Revenue Recognition

Note 4 - Revenue Recognition	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Revenue from Contract with Customer [Text Block]	NOTE 4 Revenue from Product Sales The Company has medical device revenue consisting primarily of sales of the STREAMWAY System, as well as sales of the proprietary cleaning fluid and filters for use with the STREAMWAY System. This revenue stream is reported within both the domestic and international revenue segments. The Company sells its medical device products directly to hospitals and other medical facilities using employed sales representatives and independent contractors. Purchase orders, which are governed by sales agreements in all cases, state the final terms for unit price, quantity, shipping and payment terms. The unit price is considered the observable stand-alone selling price for the arrangements. The Company sales agreement, and Terms and Conditions, is a dually executed contract providing explicit criteria supporting the sale of the STREAMWAY System. The Company considers the combination of a purchase order and acceptance of its Terms and Conditions to be a customer’s contract in all cases. Product sales for medical devices consist of a single performance obligation that the Company satisfies at a point in time. The Company recognizes product revenue when the following events have occurred: ( 1 2 3 4 may, may 30 60 Customers may one one one All amounts billed to a customer in a sales transaction for medical devices related to shipping and handling, if any, represent revenues earned for the goods provided, and these amounts have been included in revenue. Costs related to such shipping and handling billing are classified as cost of goods sold. This revenue stream is reported under the domestic and international sales segments. Revenue from Clinical Testing The Precision Oncology Insights are clinic diagnostic testing comprised of the Company’s ChemoFx and BioSpeciFx tests. The ChemoFx test determines how a patient’s tumor specimen reacts to a panel of various chemotherapy drugs, while the BioSpeciFx test evaluates the expression of a particular gene related to a patient’s tumor specimen. Revenues are recognized when control of the promised goods or services is transferred to customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. The estimated uncollectible amounts are generally considered implicit price concessions that are a reduction in revenue. Helomics payments terms vary by the agreements reached with insurance carriers and Medicare. The Company’s performance obligations are satisfied at one For service revenues, the Company estimates the transaction price which is the amount of consideration it expects to be entitled to receive in exchange for providing services based on its historical collection experience using a portfolio approach as a practical expedient to account for patient contracts as collective groups rather than individually. The Company monitors its estimates of transaction price to depict conditions that exist at each reporting date. If the Company subsequently determines that it will collect more consideration than it originally estimated for a contract with a patient, it will account for the change as an increase to the estimate of the transaction price, provided that such downward adjustment does not The Company recognizes revenue from these patients when contracts as defined in ASC 606, Revenue from Contracts with Customers 30 CRO Revenue Contract revenues are generally derived from studies conducted with biopharmaceutical and pharmaceutical companies. The specific methodology for revenue recognition is determined on a case-by-case basis according to the facts and circumstances applicable to a given contract. The Company typically uses an input method that recognizes revenue based on the Company’s efforts to satisfy the performance obligation relative to the total expected inputs to the satisfaction of that performance obligation. For contracts with multiple performance obligations, the Company allocates the contract’s transaction price to each performance obligation on the basis of the standalone selling price of each distinct good or service in the contract. Advance payments received in excess of revenues recognized are classified as deferred revenue until such time as the revenue recognition criteria have been met. Payment terms are net 30 Variable Consideration The Company records revenue from distributors and direct end customers in an amount that reflects the transaction price it expects to be entitled to after transferring control of those goods or services. The Company’s current contracts do not Warranty The Company generally provides one no not Contract Balances The Company records a receivable when it has an unconditional right to receive consideration after the performance obligations are satisfied. As of December 31, 2019 2018, $297,055 $232,602, The Company’s deferred revenues related primarily to maintenance plans of $40,384 $23,065 December 31, 2019 2018, Practical Expedients The Company has elected the practical expedient not

Note 5 - Stockholders' Equity,

Note 5 - Stockholders' Equity, Stock Options and Warrants	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	NOTE 5 Authorized Shares At the annual meeting on December 28, 2017, 24,000,000 50,000,000 $0.01 January 2, 2018. On March 22, 2019, 50,000,000 100,000,000 $0.01 2018 In January 2018, 290,000 $9.50 one 0.3 one $1.00 $2,755,087, February 21, 2018, 21,525 $0.01, $9.50 $188,066 $16,354 Share Exchange Agreement with Helomics On January 11, 2018, 2,500,000 110,000 20% March 2018, $500,000 5% 25% Share Issuance for Consulting On July 10 11, 2018, 25,000 $0.01, $11.80 75,000 $0.01, $11.70 2019 On February 27, 2019, 138,500 69,250 0.1 0.05 $10.00 fifth $9.00 $1,246,608 $1,111,888. March 1, 2019. 6,925 $11.25 February 27, 2024. On March 26, 2019, 147,875 73,938 0.1 0.05 $10.00 fifth $8.00 $1,183,101 $1,053,460. March 29, 2019. 73,937 $1.00 March 29, 2024. On October 1, 2019, 633,554 $5.00 $3,167,769 $2,811,309. October 4, 2019. 63,355 $6.25 Series E Convertible Preferred Stock In June 2019, 258 0.056857% six June 13, 2019. 12 $289,936, six September 2019. Equity Line On October 24, 2019, $15,000,000 three 104,651 $450,000 three may 2019, 122,356 $319,196 December 31, 2019, $14,680,805 Equity Incentive Plan The Company has an equity incentive plan, which allows issuance of incentive and non-qualified stock options to employees, directors and consultants of the Company, where permitted under the plan. The exercise price for each stock option is determined by the market price on the date of issuance. Vesting requirements are determined by the Board of Directors when granted and currently range from immediate to three ten Valuation and Accounting for Options and Warrants ASC 718 Compensation – Stock Compensation, (“ASC 718” 718 The Company determines the grant date fair value of options and warrants using a Black-Scholes option valuation model based upon assumptions regarding risk-free interest rate, expected dividend rate, volatility and estimated term. Beginning in 2019, 2019. The fair value of each option grant is estimated on the grant date using the Black-Scholes option valuation model with the following assumptions: Year Ended December 31, 2019 2018 Stock Options Expected dividend yield 0.0% 0.0 Expected stock price volatility 78.6% - 82.4% 66.0 Risk-free interest rate 1.50% - 2.76% 2.46% - 3.07% Expected life of options (in years) 10 10 Warrants Expected dividend yield 0.0 0.0 Expected stock price volatility 78.6% - 82.4% 59.0 Risk-free interest rate 1.39% - 2.58% 2.33% - 2.96% Expected life of options (in years) 5 5 The following summarizes transactions for stock options and warrants for the periods indicated: Stock Options Warrants Number of Average Number of Average Outstanding at December 31, 2017 276,498 $ 19.95 195,126 $ 237.40 Issued 109,886 10.13 233,615 10.67 Forfeited (19,456 ) 20.00 (1,071 ) 1,995.53 Exercised - - (65,006 ) 10.00 Outstanding at December 31, 2018 366,928 $ 17.03 362,664 $ 41.67 Issued 423,295 6.53 1,869,299 9.25 Forfeited (23,799 ) 13.30 (653 ) 3,249.28 Exercised - - (59,700 ) 0.10 Outstanding at December 31, 2019 766,424 $ 11.34 2,171,610 $ 15.26 At December 31, 2019, 669,050 $11.93 8.38 2,171,610 2019 2018 $2,250,422 $1,124,928, $201,628 21 The following summarizes the status of options and warrants outstanding at December 31, 2019: Range of Exercise Prices Shares Weighted Options: $2.61 – 6.50 157,848 9.53 $7.324 – 8.491 285,826 9.07 $9.00 – 14.70 310,882 7.50 $21.00 – 51.25 11,045 6.90 $657.50 – 5,962.50 823 4.39 Total 766,424 Warrants: $0.10 – 8.36 250,145 4.56 $10.00 1,674,088 4.22 $10.71 – 22.50 237,970 3.23 $1,237.50 9,407 0.67 Total 2,171,610 Stock options and warrants expire on various dates from January 2020 December 2029. Stock Options and Warrants Granted by the Company The following table is the listing of outstanding stock options and warrants as of December 31, 2019 Stock Options: Year Shares Price 2011 17 $ 2,812.50 2012 171 1,312.50 – 1,500.00 2013 150 1,481.25 – 5,962.50 2014 84 1,625.00 – 4,312.50 2015 401 657.50 – 862.50 2016 9,617 22.50 – 51.25 2017 235,053 10.10 – 21.00 2018 97,636 6.19 – 13.50 2019 423,295 2.61 – 9.00 Total 766,424 $0.45 – 5962.50 Warrants: Year Shares Price 2015 9,407 $ 1,237.50 2016 25,233 10.00 2017 108,295 10.71 – 22.50 2018 219,076 8.36 – 13.125 2019 1,809,599 2.50 – 11.88 Total 2,171,610 $2.50 – 3,095.00

Note 6 - Notes Receivable

Note 6 - Notes Receivable	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Financing Receivables [Text Block]	NOTE 6– The Company has a secured promissory note receivable from CytoBioscience for $1,112,524, 8% February 28, 2020. 2019, first April 2019. not first 2019. not March 2, 2020, 13 During 2018, $500,000 833,333 5% 25%. Also, during 2018, $997,500 December 31, 2018 $1,165,013 $29,215. During 2019, $975,000. April 3, 2019, $2,140,013, $70,369 $1,190,967 1. no 2

Note 7 - Notes Payable

Note 7 - Notes Payable	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Convertible Debt and Derivative Liability [Text Block]	NOTE 7 The balances of notes payable were as follows: Due Date December 31, 2019 December 31, 2018 Bridge loan March 31, 2020 $ 1,989,104 $ 2,297,727 Promissory note March 27, 2020 680,833 - Equity line borrowing May 26, 2020 18,563 - Equity line borrowing June 10, 2020 147,783 - Equity line borrowing June 20, 2020 194,943 - Dr. Schwartz note September 30, 2020 2,115,000 370,000 Total Notes Payable, gross 5,146,226 2,667,727 Less: Unamortized discount 350,426 1,032,813 Total Notes Payable, net $ 4,795,800 $ 1,634,914 Bridge Loan During September 2018, two $2,297,727 $2,000,000. 65,000 107,178 $11.55 8% February 2019, $344,659 16,667 September 2019, one $144,378 2019 $497,276 not December 31, 2019. No 2018. December 31, 2019 $1,989,104 $133,839. Each investor has the right to convert all or any part of its bridge loan into shares of the Company’s common stock at a conversion factor that is the lesser of a discounted 20 may 267,833 2019, $378,573 103,415 No 2018. Dr. Schwartz Notes In November 2018, $370,000. December 31, 2018, one $370,000 $63,028. November 30, 2018 July 15, 2019, $1,920,000 two 22,129 $8.36 February 1, 2019 first October 2019, not As of January 2020, one December 31, 2019 not February 8, 2020. January 2020, two 13 As of December 31, 2019, $2,115,000. 8% December 31, 2019 12% December 31, 2019. Helomics Investor Notes As disclosed in Note 2 $303,333 October 2019. $18,216 Promissory Note During September 2019, $847,500 $700,000. 8,857 68,237 $6.21 sixth fifth 8% 2019, one $166,667. $33,333 2019 $136,167 not December 31, 2019. December 31, 2019, $680,833 $216,587. Short Term Borrowings During 2019, six 8% 2019, $478,159 $440,000 $118,527 $6,367 2019 $35,468 not December 31, 2019. December 31, 2019 $361,289. Extension of Notes Payable Throughout 2019, 2019, $581,073 $162,750 30,000 13,000 Derivative Liability Management has concluded the September 2018 20 $221,756 $372,263 2019 2018, December 31, 2019 $50,989. On May 21, 2019, February 1, 2019 first 5,753 2019. $22,644 zero December 31, 2019 January 2020, 13 The table below discloses changes in value of the Company’s embedded derivative liabilities related to the bridge loan and the derivative included in the note payable agreements with Dr. Schwartz during the years ended December 31, 2019 December 31, 2018. Derivative liability balance at December 31, 2017 $ - Derivative instruments recognized 645,008 Gain recognized to revalue derivative instrument at fair value (372,263 ) Derivative liability balance at December 31, 2018 $ 272,745 Derivative instrument recognized 69,722 Gain recognized to revalue derivative instrument at fair value (221,756 ) Adjustments to derivative liability for warrants issued (47,078 ) Reduction of derivative liability (22,644 ) Derivative liability balance at December 31, 2019 $ 50,989

Note 8 - Loss Per Share

Note 8 - Loss Per Share	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Earnings Per Share [Text Block]	NOTE 8 The following table presents the shares used in the basic and diluted loss per common share computations: Year Ended 2019 2018 Numerator: Net loss attributable to common shareholders per common share: basic and diluted calculation $ (19,680,701 ) $ (10,086,477 ) Denominator: Weighted average common shares outstanding-basic 2,870,132 1,281,629 Effect of diluted stock options, warrants and preferred stock (1) - - Weighted average common shares outstanding-diluted 2,870,132 1,281,629 Loss per common share-basic and diluted $ (6.86 ) $ (7.87 ) ( 1 Year Ended December 31, 2019 2018 Options 766,424 366,928 Warrants 2,171,610 362,664 Convertible debt 82,751 329,409 Preferred stock: Series B 7,925 7,925 Preferred stock: Series D 350,000 - Preferred stock: Series E 594,383 -

Note 9 - Income Taxes

Note 9 - Income Taxes	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Income Tax Disclosure [Text Block]	NOTE 9– The provision for income taxes consists of an amount for taxes currently payable and a provision for tax consequences deferred to future periods. Deferred income taxes are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred income tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The Tax Reform Act was enacted December 22, 2017. January 1, 2018 34% 21%. no 100% There is no 100% Actual income tax benefit differs from statutory federal income tax benefit as follows: Year Ended December 31, 2019 2018 Statutory federal income tax benefit $ 3,977,561 $ 2,118,160 State tax benefit, net of federal taxes 368,635 66,117 Foreign tax benefit 104,050 132,931 Foreign operations tax rate differential (73,869 ) (94,373 ) State rate adjustment (17,585 ) 15,355 R&D tax credit 51,143 22,532 Nondeductible/nontaxable items (517,465 ) (118,905 ) State NOL adjustment (1,054,778 ) 746,479 OID and derivatives 141,908 (159,037 ) Helomics purchase adjustment 66,394,188 - Other 115,896 47,868 Valuation allowance increase (69,489,684 ) (2,777,127 ) Total income tax benefit $ - $ Deferred taxes consist of the following: December 31, 2019 December 31, 2018 Deferred tax assets: Noncurrent: Depreciation $ - $ 4,488 Inventory 6,891 6,991 Compensation accruals 56,670 60,905 Accruals and reserves 77,777 Deferred revenue 7,480 Charitable contribution carryover 3,740 3,972 Derivatives 10,708 57,276 Related party investments 657,633 481,652 Intangibles 295,941 2,020 NSQO compensation 1,589,430 1,019,139 NOL and credits 78,417,618 9,655,388 Total deferred tax assets 81,046,111 11,369,608 Deferred tax liabilities: Noncurrent: Original issue discount (14,021 ) (216,891 ) Depreciation (389,689 ) Total deferred tax liabilities (403,710 ) (216,891 ) Net deferred tax assets 80,642,401 11,152,717 Less: valuation allowance (80,642,401 ) (11,152,717 ) Total - $ - As a result of the Helomics merger on April 4, 2019, December 31, 2019 may The acquired NOL carryforwards from Helomics experienced an ownership change as defined in Section 382 December 2013. may December 2013, not At December 31, 2018, $40,444,754 2019, 382 $34,529,255 2022 $5,915,499 $13,114,182 December 31, 2018. 2019 $421,782 December 31, 2018. December 31, 2018, $9,603,237, $1,416,758 $132,722, At December 31, 2019, $291,476,788 2020, 382 $264,379,011 2021 $27,097,777 $213,762,905 December 31, 2019. 2020 $773,455 December 31, 2019. December 31, 2019, $58,991,353, $21,414,302, $236,746, Tax years subsequent to 2015 not no The Company recognizes interest and penalties on unrecognized tax benefits as well as interest received from favorable tax settlements within income tax expense. At December 31, 2019 2018, no

Note 10 - Leases

Note 10 - Leases	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Lessee, Operating Leases [Text Block]	NOTE 10 The Company’s corporate offices are located in Eagan, Minnesota. The lease as amended has a three January 31, 2021. 5,773 2,945 2,828 Skyline Medical Europe’s offices are located in Belgium. The Company leases around 2,000 750 1,250 June 14, 2027. Helomics’ offices are located in Pittsburgh, Pennsylvania. The lease, as amended, has a three February 28, 2021. 17,417 1,000 16,417 Lease expense under operating lease arrangements was $431,170 $69,013 2019 2018, The following table summarizes other information related to the Company’s operating leases: December 31, 2019 Weighted average remaining lease term – operating leases in years 3.28 Weighted average discount rate – operating leases 8 % The Company’s lease obligation as of December 31, 2019 2020 $ 476,468 2021 111,353 2022 43,154 2023 44,017 2024 44,897 2025 and thereafter 112,271 Total lease payments 832,160 Less interest 102,415 Present value of lease liabilities $ 729,745

Note 11 - Related Party Transac

Note 11 - Related Party Transactions	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	NOTE 11 The Audit Committee has the responsibility to review and approve all transactions to which a related party and the Company may One of the Company’s directors, Richard L. Gabriel, is the Chief Operating Officer and serves as a director of GLG Pharma (“GLG”). Tim Krochuk, a Company director until December 31, 2019, no Richard L. Gabriel is also contracted as the Chief Operating Officer for TumorGenesis. During 2018 April 1, 2019, $12,000 six May 1, 2019, one three $13,500 Dr. Carl Schwartz, the Company’s CEO, had made investments in the Company in exchange for promissory notes and common stock. See Note 7

Note 12 - Retirement Savings Pl

Note 12 - Retirement Savings Plans	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Pension and Other Postretirement Benefits Disclosure [Text Block]	NOTE 12 The Company has a pre-tax salary reduction/profit-sharing plan under the provisions of Section 401 2019 2018, 100% 4.0% $110,714 $51,647 2019 2018, no 2019 2018.

Note 13 - Subsequent Events

Note 13 - Subsequent Events	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Subsequent Events [Text Block]	NOTE 13 Equity Line Agreement During the first 2020, 943,000 $1,869,899 Short Term Borrowings During the first 2020, $1,098,684 $1,020,000 $657,105 Promissory Note On February 5, 2020, $1,450,000 $1,200,000. three first $490,000 $400,000. second March 5, 2020, $480,000 $400,000. third $480,000, 60 February 5, 2020. July 5, 2020. 8% As additional consideration, the Company issued to the investor warrants to purchase 94,631 first 92,700 second third sixth $2.992 46,875 first Letter of Intent On January 24, 2020, Completion of the transaction, which is expected to be completed in the second 2020, Term Sheet with InventaBio Tech On March 2, 2020, not 125,000 CEO Promissory Note Exchange Agreement During January 2020, two $2,115,000 12% September 30, 2020 50,000 no October 2019, not December 31, 2019 December 31, 2019 $310,000 2019. Shares Issued to Vendor On March 4, 2020, 150,000 March 2020 On March 15, 2020, 260,000 $2.12 1 one five one 2 one two $1.88 In addition, and in lieu of common shares, certain investors purchased prefunded warrants to purchase 1,390,166 $2.12 $0.0001 The sale of the offering shares and prefunded warrants resulted in gross proceeds of $3,498,612 $3,127,112 March 18, 2020, Extension of Notes Payable On March 19, 2020, March 27, 2020 March 31, 2020 June 27, 2020. $300,000 30,000 not ASC 470 50 2019 In December 2019, 19” 19 19

Significant Accounting Policies

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2019
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Nature of Operations and Continuance of Operations Predictive Oncology Inc., (the “Company” or “Predictive”) was originally incorporated on April 23, 2002 August 6, 2013, December 16, 2013, August 31, 2015, February 1, 2018, February 1, 2018. February 2, 2018. June 10, 2019, June 13, 2019. October 28, 2019, one ten October 29, 2019. The Company is a healthcare company that provides personalized medicine solution and medical devices in two 1 2 In addition, the Company’s wholly-owned subsidiary, TumorGenesis Inc. (“TumorGenesis”), is developing the next generation, patient-derived tumor models for precision cancer therapy and drug development. TumorGenesis Inc., formed during the first 2018, During the first 2018, 25% April 4, 2019, 75% The Company has incurred recurring losses from operations and has an accumulated deficit of $82,498,711. not 2019, no may $150,831 December 31, 2019 $6,213,507 December 31, 2019, six may October 2019, $15,000,000 three no three 2019, 122,356 $319,196 2020, $6,159,906, 13 not one not The Company has no
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Adopted Accounting Standards In February 2016, No. 2016 02, Leases (Topic 842 2016 02” December 15, 2018. 2016 02 January 1, 2019, $353,007 $79,252 2016 02 not The Company leases facilities under long-term operating leases that are non-cancelable and expire on various dates. At the lease commencement date, lease ROU assets and lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term, which includes all fixed obligations arising from the lease contract. If an interest rate is not 10
Use of Estimates, Policy [Policy Text Block]	Accounting Policies and Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and disclosure of contingent assets and liabilities at the date of the financial statements and during the reporting period. Actual results could materially differ from those estimates.
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents Cash and cash equivalents consist of cash on hand. The company has no December 31, 2018 December 31, 2019.
Receivable [Policy Text Block]	Receivables Receivables are reported at the amount the Company expects to collect on balances outstanding. The Company provides for probable uncollectible amounts through charges to earnings and credits to the valuation allowance based on management’s assessment of the current status of individual accounts. During 2019, $1,037,524 6
Inventory, Policy [Policy Text Block]	Inventories Inventories are stated at the lower of cost or net realizable value, with cost determined on a first first December 31, December 31, Finished goods $ 91,410 $ 58,701 Raw materials 69,821 127,003 Work-In-Process 28,925 55,362 Total $ 190,156 $ 241,066
Property, Plant and Equipment, Policy [Policy Text Block]	Fixed Assets Fixed assets are stated at cost less accumulated depreciation. Depreciation of fixed assets is computed using the straight-line method over the estimated useful lives of the respective assets. Accumulated depreciation is included in fixed assets, net on the accompanying consolidated balance sheets. Estimated useful life by asset classification is as follows: Years Computers and office equipment 3 - 7 Leasehold improvements (1) 5 Manufacturing and laboratory equipment 3 - 7 Demonstration equipment 3 Laboratory equipment 4 ( 1 Leasehold improvements are depreciated over the shorter of the useful life or the remaining lease term. The Company’s fixed assets consist of the following: December 31, December 31, Computers and office equipment $ 508,143 $ 204,903 Leasehold improvements 188,014 140,114 Manufacturing tooling 1,510,165 108,955 Demo equipment 73,051 85,246 Total 2,279,373 539,218 Less: Accumulated depreciation 771,574 358,765 Total fixed assets, net $ 1,507,799 $ 180,453 Upon retirement or sale or fixed assets, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is reflected in operations expense. Maintenance and repairs are expensed as incurred. Depreciation expense was $414,331 $84,995 2019 2018,
Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]	Intangible Assets Finite-lived intangible assets consist of patents and trademarks, licensing fees, developed technology, and customer relationships, and are amortized over their estimated useful life. The tradename is an indefinite-lived intangible asset and is not $290,552 $62,633 2019 2018, 360 Property, Plant and Equipment may not may not not 350— Intangibles—Goodwill and Other not As of December 31, 2019, $3,649,412 $964,495 December 31, 2018. The components of intangible assets were as follows: December 31, 2019 December 31, 2018 Gross Accumulated Net Carrying Gross Accumulated Net Carrying Patents & Trademarks $ 339,023 $ (195,286 ) $ 143,737 $ 318,304 $ (182,559 ) $ 135,745 Licensing Fees - - - 877,500 (48,750 ) 828,750 Developed Technology 2,882,000 (108,075 ) 2,773,925 - - - Customer Relationships 445,000 (111,250 ) 333,750 - - - Tradename 398,000 - 398,000 - - - Total $ 4,064,023 $ (414,611 ) $ 3,649,412 $ 1,195,804 $ (231,309 ) $ 964,495 The following table outlines the estimated future amortization expense related to intangible assets held as of December 31, 2019: Year ending December 31, Expense 2020 $ 305,785 2021 305,785 2022 194,535 2023 157,452 2024 157,452 Thereafter 2,130,403 Total $ 3,251,412
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]	Impairment of Long-Lived Assets The Company reviews long-lived assets, including property and equipment and intangible assets with estimable useful lives, for impairment whenever events or changes in circumstances indicate that the carrying amount of such an asset may not The recoverability of an asset to be held and used is determined by comparing the carrying amount to the estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of the asset exceeded its estimated undiscounted future cash flows, the Company recorded an impairment charge in the amount by which the carrying amount of the asset exceeds its fair value, which is determined by either a quoted market price, if any, or a value determined by utilizing discounted cash flow techniques. During 2019, $58,500 may not $770,250 No 2018.
Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]	Goodwill In accordance with ASC 350 Intangibles – Goodwill and Other not In the Helomics acquisition, the Company recorded goodwill of $23,790,290. not not first may In testing goodwill for impairment as of December 31, 2019, December 31, 2019. 2017 04 Simplifying the Test for Goodwill Impairment December 31, 2019 $8,100,000 no twelve December 31, 2018. Goodwill balance at December 31, 2018 $ - Acquired 23,790,290 Impairment (8,100,000 ) Goodwill balance at December 31, 2019 $ 15,690,290 When evaluating the fair value of Helomics reporting unit the Company used a discounted cash flow model. Key assumptions used to determine the estimated fair value included: (a) expected cash flow for the 20 3.0% 18.3% 7% The majority of the inputs used in the discounted cash flow model are unobservable and thus are considered to be Level 3 The Company will continue to monitor its reporting units to determine whether events and circumstances warrant further interim impairment testing. Goodwill is not
Fair Value Measurement, Policy [Policy Text Block]	Fair Value Measurements As outlined in ASC – 820, Fair Value Measurement 820 three Level 1 Level 2 Level 3 no The Company uses observable market data, when available, in making fair value measurements. Fair value measurements are classified according to the lowest level input that is significant to the valuation. The fair value of the Company’s investment securities, which consist of cash and cash equivalents, was determined based on Level 1 3
Revenue from Contract with Customer [Policy Text Block]	Revenue Recognition The Company recognizes revenue when it satisfies a performance obligation by transferring control of the promised goods or services to its customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. Sales taxes are imposed on the Company’s sales to nonexempt customers. The Company collects the taxes from the customers and remits the entire amounts to the governmental authorities. Sales taxes are excluded from revenue and expenses. See Note 4
Income Tax, Policy [Policy Text Block]	Income Taxes The Company accounts for income taxes in accordance with ASC 740 Income Taxes 740” 740, There is no 100% The Company reviews income tax positions expected to be taken in income tax returns to determine if there are any income tax uncertainties. The Company recognizes tax benefits from uncertain tax positions only if it is more likely than not no Under Internal Revenue Code Section 382, may not not 382 may 382 2020. Tax years subsequent to 2015
Advertising Cost [Policy Text Block]	Advertising Advertising costs are expensed as incurred. Advertising expenses were $21,166 2019 $43,548 2018.
Research and Development Expense, Policy [Policy Text Block]	Research and Development Research and development costs are charged to operations as incurred. Research and development costs were $422,964 $526,257 2019 2018,
Offering Costs [Policy Text Block]	Offering Costs Costs incurred which are direct and incremental to an offering of the Company’s securities are deferred and charged against the proceeds of the offering, unless such costs are deemed to be insignificant in which case they are expensed as incurred. During 2019, $324,459
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Credit Risk Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash. The Company places its cash with high credit quality financial institutions and, by policy, generally limits the amount of credit exposure to any one no
Standard Product Warranty, Policy [Policy Text Block]	Product Warranty Costs In 2019 2018, $15,717 $10,682,
Other Expense Policy [Policy Text Block]	Other Expense Other expense consisted primarily of interest expense, payment penalties, amortization of original issue discounts, and loss on debt extinguishment associated to the Company’s notes payable.
Segment Reporting, Policy [Policy Text Block]	Segments The Company has determined its operating segments in accordance with ASC 280 Segment Reporting During the fourth 2019, one not 2018, three 4 December 31, 2019 2 not Year Ended December 31, 2019 Domestic International Helomics Corporate Total Revenue $ 1,275,048 $ 88,070 $ 48,447 - $ 1,411,565 Depreciation and Amortization (43,728 ) (4,692 ) (556,538 ) (99,925 ) (704,883 ) Impairment expense - - (8,100,000 ) (770,250 ) (8,870,250 ) Loss on equity method investment - - - (439,637 ) (439,637 ) Segment Loss $ (2,783,531 ) $ (351,759 ) $ (12,354,108 ) $ (3,901,368 ) $ (19,390,766 ) December 31, 2019 Domestic International Helomics Corporate Total Assets $ 670,841 $ 298,952 $ 21,275,306 $ 130,411 $ 22,375,510 In 2018, December 31, 2018 Domestic International Helomics Corporate Total Assets $ 932,367 $ 41,377 - $ 2,735,255 $ 3,708,999
Risks and Uncertainties Policy [Policy Text Block]	Risks and Uncertainties The Company is subject to risks common to companies in the medical device and biopharmaceutical industries, including, but not

Note 1 - Summary of Significa_2

Note 1 - Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2019
Notes Tables
Schedule of Inventory, Current [Table Text Block]	December 31, December 31, Finished goods $ 91,410 $ 58,701 Raw materials 69,821 127,003 Work-In-Process 28,925 55,362 Total $ 190,156 $ 241,066
Property Plant and Equipment Useful Life [Table Text Block]	Years Computers and office equipment 3 - 7 Leasehold improvements (1) 5 Manufacturing and laboratory equipment 3 - 7 Demonstration equipment 3 Laboratory equipment 4
Property, Plant and Equipment [Table Text Block]	December 31, December 31, Computers and office equipment $ 508,143 $ 204,903 Leasehold improvements 188,014 140,114 Manufacturing tooling 1,510,165 108,955 Demo equipment 73,051 85,246 Total 2,279,373 539,218 Less: Accumulated depreciation 771,574 358,765 Total fixed assets, net $ 1,507,799 $ 180,453
Schedule of Finite-Lived Intangible Assets [Table Text Block]	December 31, 2019 December 31, 2018 Gross Accumulated Net Carrying Gross Accumulated Net Carrying Patents & Trademarks $ 339,023 $ (195,286 ) $ 143,737 $ 318,304 $ (182,559 ) $ 135,745 Licensing Fees - - - 877,500 (48,750 ) 828,750 Developed Technology 2,882,000 (108,075 ) 2,773,925 - - - Customer Relationships 445,000 (111,250 ) 333,750 - - - Tradename 398,000 - 398,000 - - - Total $ 4,064,023 $ (414,611 ) $ 3,649,412 $ 1,195,804 $ (231,309 ) $ 964,495
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	Year ending December 31, Expense 2020 $ 305,785 2021 305,785 2022 194,535 2023 157,452 2024 157,452 Thereafter 2,130,403 Total $ 3,251,412
Schedule of Goodwill [Table Text Block]	Goodwill balance at December 31, 2018 $ - Acquired 23,790,290 Impairment (8,100,000 ) Goodwill balance at December 31, 2019 $ 15,690,290
Schedule of Segment Reporting Information, by Segment [Table Text Block]	Year Ended December 31, 2019 Domestic International Helomics Corporate Total Revenue $ 1,275,048 $ 88,070 $ 48,447 - $ 1,411,565 Depreciation and Amortization (43,728 ) (4,692 ) (556,538 ) (99,925 ) (704,883 ) Impairment expense - - (8,100,000 ) (770,250 ) (8,870,250 ) Loss on equity method investment - - - (439,637 ) (439,637 ) Segment Loss $ (2,783,531 ) $ (351,759 ) $ (12,354,108 ) $ (3,901,368 ) $ (19,390,766 ) December 31, 2019 Domestic International Helomics Corporate Total Assets $ 670,841 $ 298,952 $ 21,275,306 $ 130,411 $ 22,375,510 December 31, 2018 Domestic International Helomics Corporate Total Assets $ 932,367 $ 41,377 - $ 2,735,255 $ 3,708,999

Note 2 - Helomics Acquisition (

Note 2 - Helomics Acquisition (Tables)	12 Months Ended
	Dec. 31, 2019
Notes Tables
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]	Value of shares to Helomics shareholders (i) $ 5,612,250 Value of Helomics notes receivable forgiven (ii) 2,210,381 Value of shares to extinguish debt (iii) 6,463,309 Value of warrants issued (iv) 6,261,590 Gain on revaluation of equity method investment (v) 6,164,260 Fair value of the consideration $ 26,711,790 Less assets acquired: Cash and cash equivalents 248,102 Accounts receivable 207,769 Inventory 17,727 Prepaid expenses 15,321 Fixed assets, net 1,749,080 Intangible assets 3,725,000 Lease right of use assets 780,594 Plus liabilities assumed: Accounts payable 2,374,596 Note Payable 303,333 Accrued expenses 363,569 Lease Liability – Net of Long-term Portion 422,126 Lease liability 358,468 Total assets acquired and liabilities assumed (2,921,501 ) Goodwill $ 23,790,290
Business Acquisition, Pro Forma Information [Table Text Block]	Year Ended December 31, 2019 2018 Unaudited Revenue $ 1,457,625 $ 1,812,433 Net loss attributable to common shareholders $ (20,947,033 ) (12,419,423 )

Note 3 - Equity Method Invest_2

Note 3 - Equity Method Investment (Tables)	12 Months Ended
	Dec. 31, 2019
Notes Tables
Equity Method Investments [Table Text Block]	December 31, 2018 Current assets $ 419,266 Non-current assets 2,046,347 Total assets 2,465,613 Current liabilities 12,247,174 Total liabilities 12,247,174 Period January 1, 2019 to April 4, 2019 Year Ended December 31, 2018 Revenue $ 45,835 $ 523,546 Gross margin 7,348 214,426 Net loss on Operations (1,555,542 ) (9,452,835 ) Net Loss (1,166,656 ) 1 (7,159,255 ) 1

Note 5 - Stockholders' Equity_2

Note 5 - Stockholders' Equity, Stock Options and Warrants (Tables)	12 Months Ended
	Dec. 31, 2019
Notes Tables
Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]	Year Ended December 31, 2019 2018 Stock Options Expected dividend yield 0.0% 0.0 Expected stock price volatility 78.6% - 82.4% 66.0 Risk-free interest rate 1.50% - 2.76% 2.46% - 3.07% Expected life of options (in years) 10 10 Warrants Expected dividend yield 0.0 0.0 Expected stock price volatility 78.6% - 82.4% 59.0 Risk-free interest rate 1.39% - 2.58% 2.33% - 2.96% Expected life of options (in years) 5 5
Share-based Payment Arrangement, Activity [Table Text Block]	Stock Options Warrants Number of Average Number of Average Outstanding at December 31, 2017 276,498 $ 19.95 195,126 $ 237.40 Issued 109,886 10.13 233,615 10.67 Forfeited (19,456 ) 20.00 (1,071 ) 1,995.53 Exercised - - (65,006 ) 10.00 Outstanding at December 31, 2018 366,928 $ 17.03 362,664 $ 41.67 Issued 423,295 6.53 1,869,299 9.25 Forfeited (23,799 ) 13.30 (653 ) 3,249.28 Exercised - - (59,700 ) 0.10 Outstanding at December 31, 2019 766,424 $ 11.34 2,171,610 $ 15.26
Schedule of Share-based Compensation Shares Authorized Under Stock Option and Warrant Plans by Exercise Price Range [Table Text Block]	Range of Exercise Prices Shares Weighted Options: $2.61 – 6.50 157,848 9.53 $7.324 – 8.491 285,826 9.07 $9.00 – 14.70 310,882 7.50 $21.00 – 51.25 11,045 6.90 $657.50 – 5,962.50 823 4.39 Total 766,424 Warrants: $0.10 – 8.36 250,145 4.56 $10.00 1,674,088 4.22 $10.71 – 22.50 237,970 3.23 $1,237.50 9,407 0.67 Total 2,171,610
Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]	Year Shares Price 2011 17 $ 2,812.50 2012 171 1,312.50 – 1,500.00 2013 150 1,481.25 – 5,962.50 2014 84 1,625.00 – 4,312.50 2015 401 657.50 – 862.50 2016 9,617 22.50 – 51.25 2017 235,053 10.10 – 21.00 2018 97,636 6.19 – 13.50 2019 423,295 2.61 – 9.00 Total 766,424 $0.45 – 5962.50 Year Shares Price 2015 9,407 $ 1,237.50 2016 25,233 10.00 2017 108,295 10.71 – 22.50 2018 219,076 8.36 – 13.125 2019 1,809,599 2.50 – 11.88 Total 2,171,610 $2.50 – 3,095.00

Note 7 - Notes Payable (Tables)

Note 7 - Notes Payable (Tables)	12 Months Ended
	Dec. 31, 2019
Notes Tables
Schedule of Short-term Debt [Table Text Block]	Due Date December 31, 2019 December 31, 2018 Bridge loan March 31, 2020 $ 1,989,104 $ 2,297,727 Promissory note March 27, 2020 680,833 - Equity line borrowing May 26, 2020 18,563 - Equity line borrowing June 10, 2020 147,783 - Equity line borrowing June 20, 2020 194,943 - Dr. Schwartz note September 30, 2020 2,115,000 370,000 Total Notes Payable, gross 5,146,226 2,667,727 Less: Unamortized discount 350,426 1,032,813 Total Notes Payable, net $ 4,795,800 $ 1,634,914
Schedule of Derivative Liabilities at Fair Value [Table Text Block]	Derivative liability balance at December 31, 2017 $ - Derivative instruments recognized 645,008 Gain recognized to revalue derivative instrument at fair value (372,263 ) Derivative liability balance at December 31, 2018 $ 272,745 Derivative instrument recognized 69,722 Gain recognized to revalue derivative instrument at fair value (221,756 ) Adjustments to derivative liability for warrants issued (47,078 ) Reduction of derivative liability (22,644 ) Derivative liability balance at December 31, 2019 $ 50,989

Note 8 - Loss Per Share (Tables

Note 8 - Loss Per Share (Tables)	12 Months Ended
	Dec. 31, 2019
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Year Ended 2019 2018 Numerator: Net loss attributable to common shareholders per common share: basic and diluted calculation $ (19,680,701 ) $ (10,086,477 ) Denominator: Weighted average common shares outstanding-basic 2,870,132 1,281,629 Effect of diluted stock options, warrants and preferred stock (1) - - Weighted average common shares outstanding-diluted 2,870,132 1,281,629 Loss per common share-basic and diluted $ (6.86 ) $ (7.87 )
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Year Ended December 31, 2019 2018 Options 766,424 366,928 Warrants 2,171,610 362,664 Convertible debt 82,751 329,409 Preferred stock: Series B 7,925 7,925 Preferred stock: Series D 350,000 - Preferred stock: Series E 594,383 -

Note 9 - Income Taxes (Tables)

Note 9 - Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2019
Notes Tables
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	Year Ended December 31, 2019 2018 Statutory federal income tax benefit $ 3,977,561 $ 2,118,160 State tax benefit, net of federal taxes 368,635 66,117 Foreign tax benefit 104,050 132,931 Foreign operations tax rate differential (73,869 ) (94,373 ) State rate adjustment (17,585 ) 15,355 R&D tax credit 51,143 22,532 Nondeductible/nontaxable items (517,465 ) (118,905 ) State NOL adjustment (1,054,778 ) 746,479 OID and derivatives 141,908 (159,037 ) Helomics purchase adjustment 66,394,188 - Other 115,896 47,868 Valuation allowance increase (69,489,684 ) (2,777,127 ) Total income tax benefit $ - $
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	December 31, 2019 December 31, 2018 Deferred tax assets: Noncurrent: Depreciation $ - $ 4,488 Inventory 6,891 6,991 Compensation accruals 56,670 60,905 Accruals and reserves 77,777 Deferred revenue 7,480 Charitable contribution carryover 3,740 3,972 Derivatives 10,708 57,276 Related party investments 657,633 481,652 Intangibles 295,941 2,020 NSQO compensation 1,589,430 1,019,139 NOL and credits 78,417,618 9,655,388 Total deferred tax assets 81,046,111 11,369,608 Deferred tax liabilities: Noncurrent: Original issue discount (14,021 ) (216,891 ) Depreciation (389,689 ) Total deferred tax liabilities (403,710 ) (216,891 ) Net deferred tax assets 80,642,401 11,152,717 Less: valuation allowance (80,642,401 ) (11,152,717 ) Total - $ -

Note 10 - Leases (Tables)

Note 10 - Leases (Tables)	12 Months Ended
	Dec. 31, 2019
Notes Tables
Lease, Cost [Table Text Block]	December 31, 2019 Weighted average remaining lease term – operating leases in years 3.28 Weighted average discount rate – operating leases 8 %
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	2020 $ 476,468 2021 111,353 2022 43,154 2023 44,017 2024 44,897 2025 and thereafter 112,271 Total lease payments 832,160 Less interest 102,415 Present value of lease liabilities $ 729,745

Note 1 - Summary of Significa_3

Note 1 - Summary of Significant Accounting Policies (Details Textual)	Oct. 28, 2019	Oct. 24, 2019USD ($)shares	Oct. 31, 2019USD ($)shares	Mar. 27, 2020USD ($)	Dec. 31, 2019USD ($)shares	Dec. 31, 2018USD ($)	Apr. 04, 2019USD ($)	Jan. 01, 2019USD ($)	Mar. 31, 2018
Retained Earnings (Accumulated Deficit), Ending Balance					$ (82,498,711)	$ (63,107,945)
Cash and Cash Equivalents, at Carrying Value, Ending Balance					150,831	162,152
Long-term Debt, Current Maturities, Total					6,213,507
Stock Issued During Period, Value, New Issues						2,755,087
Operating Lease, Right-of-Use Asset					729,745
Operating Lease, Liability, Current					459,481
Cash Equivalents, at Carrying Value, Total					0	0
Depreciation, Total					414,331	84,995
Amortization of Intangible Assets, Total					290,552	62,633
Intangible Assets, Net (Excluding Goodwill), Total					3,649,412	964,495
Impairment of Intangible Assets (Excluding Goodwill), Total					770,250
Goodwill, Ending Balance					15,690,290
Goodwill, Impairment Loss					8,100,000	0
Income Tax Expense (Benefit), Total					0
Unrecognized Tax Benefits, Ending Balance					0
Liability for Uncertainty in Income Taxes, Current					$ 0
Open Tax Year					2015 2016 2017 2018 2019
Advertising Expense					$ 21,166	43,548
Research and Development Expense, Total					422,964	526,257
Capitalized Offering Costs					324,459
Product Warranty Expense					$ 15,717	$ 10,682
Measurement Input, Expected Cash Flow Term [Member]
Reporting Unit Measurement Input					20
Measurement Input, Long-term Revenue Growth Rate [Member]
Reporting Unit Measurement Input					3
Measurement Input, Discount Rate [Member]
Reporting Unit Measurement Input					18.3
Measurement Input, Risk Premium [Member]
Reporting Unit Measurement Input					7
Licensing Agreements [Member]
Amortization of Intangible Assets, Total					$ 58,500
Impairment of Intangible Assets (Excluding Goodwill), Total					770,250
Promissory Notes Receivable [Member]
Financing Receivable, Allowance for Credit Loss, Ending Balance					$ 1,037,524
Accounting Standards Update 2016-02 [Member]
Operating Lease, Right-of-Use Asset								$ 353,007
Operating Lease, Liability, Current								$ 79,252
Subsequent Event [Member]
Proceeds from Debt and Equity Financing, Net				$ 6,159,906
Equity Line Purchase Agreement [Member]
Issuance or Sale of Equity, Can Be Raised		$ 15,000,000
Stock Issued During Period, Shares, New Issues | shares		104,651			122,356
Stock Issued During Period, Value, New Issues		$ 450,000			$ 319,196
Equity Line Purchase Agreement [Member] | Investor [Member]
Issuance or Sale of Equity, Can Be Raised			$ 15,000,000
Stock Issued During Period, Shares, New Issues | shares			122,356
Stock Issued During Period, Value, New Issues			$ 319,196
Helomics Holding Corp. [Member]
Business Combination, Step Acquisition, Equity Interest in Acquiree, Percentage									25.00%
Business Acquisition, Percentage of Voting Interests Acquired							75.00%
Goodwill, Ending Balance							$ 23,790,290
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio	10

Note 1 - Summary of Significa_4

Note 1 - Summary of Significant Accounting Policies - Schedule of Inventory (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Finished goods	$ 91,410	$ 58,701
Raw materials	69,821	127,003
Work-In-Process	28,925	55,362
Total	$ 190,156	$ 241,066

Note 1 - Summary of Significa_5

Note 1 - Summary of Significant Accounting Policies - Schedule of Property, Plant and Equipment, Useful Life (Details)	12 Months Ended
	Dec. 31, 2019
Leasehold Improvements [Member]
Property, plant, and equipment, useful life (Year)	5 years	[1]
Demo Equipment [Member]
Property, plant, and equipment, useful life (Year)	3 years
Laboratory Equipment [Member]
Property, plant, and equipment, useful life (Year)	4 years
Minimum [Member] | Office Equipment [Member]
Property, plant, and equipment, useful life (Year)	3 years
Minimum [Member] | Manufacturing Tooling [Member]
Property, plant, and equipment, useful life (Year)	3 years
Maximum [Member] | Office Equipment [Member]
Property, plant, and equipment, useful life (Year)	7 years
Maximum [Member] | Manufacturing Tooling [Member]
Property, plant, and equipment, useful life (Year)	7 years
[1]	Leasehold improvements are depreciated over the shorter of the useful life or the remaining lease term.

Note 1 - Summary of Significa_6

Note 1 - Summary of Significant Accounting Policies - Schedule of Property, Plant and Equipment (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Property, Plant, and Equipment Gross	$ 2,279,373	$ 539,218
Less: Accumulated depreciation	771,574	358,765
Total fixed assets, net	1,507,799	180,453
Office Equipment [Member]
Property, Plant, and Equipment Gross	508,143	204,903
Leasehold Improvements [Member]
Property, Plant, and Equipment Gross	188,014	140,114
Manufacturing Tooling [Member]
Property, Plant, and Equipment Gross	1,510,165	108,955
Demo Equipment [Member]
Property, Plant, and Equipment Gross	$ 73,051	$ 85,246

Note 1 - Summary of Significa_7

Note 1 - Summary of Significant Accounting Policies - Components of Intangible Assets (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Accumulated Amortization	$ (414,611)	$ (231,309)
Net Carrying Amount	3,251,412
Total	4,064,023	1,195,804
Intangibles, net	3,649,412	964,495
Trade Names [Member]
Tradename	398,000
Patents and Trademarks [Member]
Gross Carrying Costs	339,023	318,304
Accumulated Amortization	(195,286)	(182,559)
Net Carrying Amount	143,737	135,745
Licensing Agreements [Member]
Gross Carrying Costs		877,500
Accumulated Amortization		(48,750)
Net Carrying Amount		828,750
Developed Technology Rights [Member]
Gross Carrying Costs	2,882,000
Accumulated Amortization	(108,075)
Net Carrying Amount	2,773,925
Customer Relationships [Member]
Gross Carrying Costs	445,000
Accumulated Amortization	(111,250)
Net Carrying Amount	$ 333,750

Note 1 - Summary of Significa_8

Note 1 - Summary of Significant Accounting Policies - Estimated Future Amortization Expense (Details)	Dec. 31, 2019USD ($)
2020	$ 305,785
2021	305,785
2022	194,535
2023	157,452
2024	157,452
Thereafter	2,130,403
Total	$ 3,251,412

Note 1 - Summary of Significa_9

Note 1 - Summary of Significant Accounting Policies - Goodwill (Details) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Goodwill
Acquired	23,790,290
Impairment	(8,100,000)	$ 0
Goodwill	$ 15,690,290

Note 1 - Summary of Signific_10

Note 1 - Summary of Significant Accounting Policies - Segments (Details) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Revenue	$ 1,411,565	$ 1,411,655
Depreciation and Amortization	(704,883)
Impairment expense	(8,870,250)
Loss on equity method investment	(439,637)	(2,293,580)
Segment Loss	(19,390,766)	(10,086,477)
Assets	22,375,510	3,708,999
Domestic [Member]
Revenue	1,275,048
Depreciation and Amortization	(43,728)
Impairment expense
Loss on equity method investment
Segment Loss	(2,783,531)
Assets	670,841	932,367
International [Member]
Revenue	88,070
Depreciation and Amortization	(4,692)
Impairment expense
Loss on equity method investment
Segment Loss	(351,759)
Assets	298,952	41,377
Helomics Segment [Member]
Revenue	48,447
Depreciation and Amortization	(556,538)
Impairment expense	(8,100,000)
Loss on equity method investment
Segment Loss	(12,354,108)
Assets	21,275,306
Corporate Segment [Member]
Revenue
Depreciation and Amortization	(99,925)
Impairment expense	(770,250)
Loss on equity method investment	(439,637)
Segment Loss	(3,901,368)
Assets	$ 130,411	$ 2,735,255

Note 2 - Helomics Acquisition_2

Note 2 - Helomics Acquisition (Details Textual) - USD ($)		Apr. 04, 2019	Dec. 31, 2019	Dec. 31, 2018
Stock Issued During Period, Value, Extinguishment of Debt			$ 6,463,309
Warrants Issued			47,078
Debt Instrument, Face Amount			5,146,226	2,667,727
Goodwill, Ending Balance			$ 15,690,290
Notes Issued to Helomics' Noteholders [Member]
Debt Instrument, Face Amount		$ 303,333
Warrants Held by Noteholders [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 1
Helomics Holding Corp. [Member]
Business Acquisition, Percentage of Voting Interests Acquired		75.00%
Business Combination, Acquisition Related Costs		$ 656,615
Business Combination, Consideration Transferred, Total		26,711,790
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable	[1]	5,612,250
Business Combination, Notes and Interest Due Forgave	[2]	$ 2,210,381
Stock Issued During Period, Shares, Extinguishment of Debt		863,732
Stock Issued During Period, Value, Extinguishment of Debt	[3]	$ 6,463,309
Stock Issued During Period, Shares, Acquisitions		23,741,772
Warrants Issued	[4]	$ 6,261,590
Business Acquisition, Revaluation, Gain (Loss) on Acquisition	[5]	6,164,260
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill, Total		3,725,000
Goodwill, Ending Balance		23,790,290
Helomics Holding Corp. [Member] | Trade Names [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill, Total		398,000
Helomics Holding Corp. [Member] | Customer Relationships [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill, Total		$ 445,000
Finite-Lived Intangible Asset, Useful Life		3 years
Helomics Holding Corp. [Member] | Developed Technology Rights [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill, Total		$ 2,882,000
Finite-Lived Intangible Asset, Useful Life		20 years
Helomics Holding Corp. [Member] | Warrants Issued to Holders of Helomics Notes and Warrants [Member]
Class of Warrant or Right Issued During Period		1,425,506
Helomics Holding Corp. [Member] | Warrants Held by Other Parties [Member]
Class of Warrant or Right Issued During Period		59,700
Helomics Holding Corp. [Member] | Common Stock [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares		400,000
Helomics Holding Corp. [Member] | Series D Convertible Preferred Stock [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares		3,500,000
[1]	Upon the acquisition, all outstanding shares of Helomics stock not already held by the Company were converted into the right to receive a proportionate share of 400,000 shares of common stock and 3,500,000 shares of Series D convertible preferred stock of the Company. The fair value of these shares on the date of issuance was $5,612,250;
[2]	the Company forgave notes and interest due from Helomics relating to previous cash advances equaling $2,210,381;
[3]	the Company eliminated debt owed by Helomics to noteholders by issuing 863,732 shares of common stock to the noteholders, the value of the shares was $6,463,309;
[4]	the Company issued 14,245,063 warrants in exchange for warrants to purchase 23,741,772 shares of Helomics common stock to the Helomics noteholders agreeing to extinguish or extend their notes. An additional 597,000 warrants were exchanged for warrants held by other parties; the total consideration of all the exchanged warrants was valued by using the Black Scholes method and equaled $6,261,591;
[5]	as the Company's acquisition of Helomics was a business combination achieved in stages, the initial 25% purchase of Helomics in 2018 was required to be revalued at current fair value on the acquisition date. Immediately prior to the acquisition date the recorded value of the equity method investment was zero. On the acquisition date the Company determined the fair value of the previous equity method investment was $6,164,260 and recorded a gain for the same amount in order to recognize the investment at its fair value. The gain was calculated as the difference between the implied fair value of the Company’s previous equity method investment in Helomics and the recorded book value immediately prior to the acquisition date. The implied fair value was calculated based on the purchase consideration exchanged to acquire the remaining 75% of Helomics and factoring a 10% discount for lack of control.

Note 2 - Helomics Acquisition -

Note 2 - Helomics Acquisition - Fair value of Assets and Liabilities Assumed (Details) - USD ($)		Apr. 04, 2019	Dec. 31, 2019	Dec. 31, 2018
Value of shares to extinguish debt (iii)			$ 6,463,309
Value of warrants issued (iv)			47,078
Goodwill, Ending Balance			$ 15,690,290
Helomics Holding Corp. [Member]
Value of shares to Helomics shareholders (i)	[1]	$ 5,612,250
Value of Helomics notes receivable forgiven (ii)	[2]	2,210,381
Value of shares to extinguish debt (iii)	[3]	6,463,309
Value of warrants issued (iv)	[4]	6,261,590
Business Acquisition, Revaluation, Gain (Loss) on Acquisition	[5]	6,164,260
Fair value of the consideration		26,711,790
Cash and cash equivalents		248,102
Accounts receivable		207,769
Inventory		17,727
Prepaid expenses		15,321
Fixed assets, net		1,749,080
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill, Total		3,725,000
Lease right of use assets		780,594
Accounts payable		2,374,596
Note Payable		303,333
Accrued expenses		363,569
Lease Liability – Net of Long-term Portion		422,126
Lease liability		358,468
Total assets acquired and liabilities assumed		(2,921,501)
Goodwill, Ending Balance		$ 23,790,290
[1]	Upon the acquisition, all outstanding shares of Helomics stock not already held by the Company were converted into the right to receive a proportionate share of 400,000 shares of common stock and 3,500,000 shares of Series D convertible preferred stock of the Company. The fair value of these shares on the date of issuance was $5,612,250;
[2]	the Company forgave notes and interest due from Helomics relating to previous cash advances equaling $2,210,381;
[3]	the Company eliminated debt owed by Helomics to noteholders by issuing 863,732 shares of common stock to the noteholders, the value of the shares was $6,463,309;
[4]	the Company issued 14,245,063 warrants in exchange for warrants to purchase 23,741,772 shares of Helomics common stock to the Helomics noteholders agreeing to extinguish or extend their notes. An additional 597,000 warrants were exchanged for warrants held by other parties; the total consideration of all the exchanged warrants was valued by using the Black Scholes method and equaled $6,261,591;
[5]	as the Company's acquisition of Helomics was a business combination achieved in stages, the initial 25% purchase of Helomics in 2018 was required to be revalued at current fair value on the acquisition date. Immediately prior to the acquisition date the recorded value of the equity method investment was zero. On the acquisition date the Company determined the fair value of the previous equity method investment was $6,164,260 and recorded a gain for the same amount in order to recognize the investment at its fair value. The gain was calculated as the difference between the implied fair value of the Company’s previous equity method investment in Helomics and the recorded book value immediately prior to the acquisition date. The implied fair value was calculated based on the purchase consideration exchanged to acquire the remaining 75% of Helomics and factoring a 10% discount for lack of control.

Note 2 - Helomics Acquisition_3

Note 2 - Helomics Acquisition - Pro Forma Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Revenue	$ 1,457,625	$ 1,812,433
Net loss attributable to common shareholders	$ (20,947,033)	$ (12,419,423)

Note 3 - Equity Method Invest_3

Note 3 - Equity Method Investment (Details Textual) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Apr. 04, 2019	Feb. 27, 2018
Income (Loss) from Equity Method Investments, Total		$ (439,637)	$ (2,293,580)
Helomics Holding Corp. [Member]
Equity Method Investment, Ownership Percentage, Purchased During Period	25.00%
Equity Method Investments			0
Income (Loss) from Equity Method Investments, Total		$ (439,637)	(2,293,580)
Equity Method Investment, Ownership Percentage				75.00%	80.00%
Financing Receivable, after Allowance for Credit Loss, Total			413,683
Financing Receivable, before Allowance for Credit Loss, Total			1,165,013
Fair Value Adjustment of Notes Receivable			$ 751,330

Note 3 - Equity Method Invest_4

Note 3 - Equity Method Investment - Summary of Equity Method Investments (Details) - USD ($)		3 Months Ended	12 Months Ended
		Apr. 04, 2019	Dec. 31, 2018
Gross margin		$ (1,555,542)	$ (9,452,835)
Net Loss	[1]	(1,166,656)	(7,159,255)
Helomics Holding Corp. [Member]
Current assets			419,266
Non-current assets			2,046,347
Total assets			2,465,613
Current liabilities			12,247,174
Total liabilities			12,247,174
Revenue		45,835	523,546
Gross margin		$ 7,348	$ 214,426
[1]	The loss to investee was calculated at 80% for the initial period of ownership, January 11, 2018 – February 27, 2018, and at 75% for the period of February 28, 2018 – April 4, 2019 at the current equity investment percentage owned by the Company.

Note 4 - Revenue Recognition (D

Note 4 - Revenue Recognition (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Maintenance Plan, Service Requirement, Period Subsequent to One Year Anniversary of Invoice	1 year
Contract with Customer, Asset, Allowance for Credit Loss, Ending Balance	$ 297,055	$ 232,602
Contract with Customer, Liability, Current	$ 40,384	$ 23,065
Maintenance [Member]
Revenue, Performance Obligation, Timing	1 year
Minimum [Member]
Standard Payment Term for Customers	30 days
Maximum [Member]
Standard Payment Term for Customers	60 days

Note 5 - Stockholders' Equity_3

Note 5 - Stockholders' Equity, Stock Options and Warrants (Details Textual)	Oct. 24, 2019USD ($)shares	Oct. 01, 2019USD ($)$ / sharesshares	Mar. 26, 2019USD ($)$ / sharesshares	Feb. 27, 2019USD ($)$ / sharesshares	Jul. 11, 2018$ / sharesshares	Jul. 10, 2018$ / sharesshares	Feb. 21, 2018$ / sharesshares	Jan. 11, 2018shares	Jun. 30, 2019USD ($)shares	Jan. 31, 2018USD ($)$ / sharesshares	Dec. 31, 2019USD ($)$ / sharesshares	Dec. 31, 2018USD ($)$ / sharesshares	Oct. 04, 2019$ / sharesshares	Mar. 29, 2019$ / sharesshares	Mar. 22, 2019$ / sharesshares	Mar. 01, 2019$ / sharesshares	Mar. 31, 2018USD ($)	Dec. 28, 2017$ / sharesshares	Jan. 29, 2017shares
Common Stock, Shares Authorized											100,000,000	50,000,000			100,000,000			50,000,000	24,000,000
Common Stock, Par or Stated Value Per Share | $ / shares					$ 0.01	$ 0.01	$ 0.01				$ 0.01	$ 0.01			$ 0.01			$ 0.01
Shares Issued, Price Per Share | $ / shares					$ 11.70	$ 11.80
Stock Issued During Period, Shares, Issued for Services						25,000
Stock Issued During Period, Share, Issued in Escrow					75,000
Proceeds from Issuance of Common Stock | $											$ 5,323,018	$ 2,959,509
Stock Issued During Period, Value, New Issues | $												2,755,087
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number											669,050
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price | $ / shares											$ 11.93
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term											8 years 138 days
Class of Warrant or Right Number of Warrants Vested and Exercisable											2,171,610
Share-based Payment Arrangement, Expense | $											$ 2,250,422	$ 1,124,928
Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount | $											$ 201,628
Share-based Payment Arrangement, Option [Member]
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition											1 year 270 days
Series E Convertible Preferred Stock [Member]
Stock Issued During Period, Shares, Convertible Preferred Shares Issued									258
Convertible Preferred Stock, Conversion Rate									0.00056857
Preferred Stock, Beneficial Conversion Feature | $									$ 289,936
Maximum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares											$ 3,095
Maximum [Member] | Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period											10 years
Helomics Holding Corp. [Member]
Stock Issued During Period, Shares, New Issues								110,000
Share Exchange Agreement, Shares Received								2,500,000
Share Exchange Agreement, Convertible Notes Receivable | $																	$ 500,000
Share Exchange Agreement, Convertible Notes, Percent of Stock												5.00%					5.00%
Share Exchange Agreement, Potential Interest																	25.00%
Series E Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares												$ 10
The 2019 Offering Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right				0.05
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares			$ 10	$ 10
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			73,938	69,250
Warrants and Rights Outstanding, Term				5 years
The 2019 Offering Warrants [Member] | Dawson James Securities, Inc. and Paulson Investment Company, LLC [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares													$ 6.25	$ 1		$ 11.25
Class of Warrant or Right, Number of Securities Called by Warrants or Rights														73,937
The 2019 Offering Warrants [Member] | Dawson James Securities, Inc. and Paulson Investment Company, LLC [Member] | Maximum [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights													63,355
Right to Purchase Units [Member] | Dawson James Securities, Inc. and Paulson Investment Company, LLC [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights																6,925
The 2018 Public Offering [Member]
Stock Issued During Period, Shares, New Issues										290,000
Share Price | $ / shares										$ 9.50
Share Per Each Unit										1
Proceeds from Issuance or Sale of Equity, Total | $										$ 2,755,087
Proceeds from Issuance or Sale of Equity, Net of Stock Issuance Costs | $										188,066
Payments of Stock Issuance Costs | $										$ 16,354
The 2018 Public Offering [Member] | Series E Warrants [Member]
Class of Warrant or Right, Issued per Unit										0.3
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right										1
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares										$ 1
Over-Allotment Option [Member]
Stock Issued During Period, Shares, New Issues							21,525
Shares Issued, Price Per Share | $ / shares							$ 9.50					$ 9.497
Stock Issued During Period, Value, New Issues | $												$ 204,422
The 2019 Offering [Member]
Stock Issued During Period, Shares, New Issues		633,554	147,875	138,500
Shares Issued, Price Per Share | $ / shares		$ 5	$ 8	$ 9
Share Per Each Unit				0.1
Proceeds from Issuance or Sale of Equity, Total | $			$ 1,183,101	$ 1,246,608
Proceeds from Issuance or Sale of Equity, Net of Stock Issuance Costs | $		$ 2,811,309	$ 1,053,460	$ 1,111,888
Unit Agreement Number of Shares of Common Stock Included in Each Unit			0.1
Unit Agreement Number of Warrants Included in Each Unit			0.05
Proceeds from Issuance of Common Stock | $		$ 3,167,769
Equity Line Purchase Agreement [Member]
Stock Issued During Period, Shares, New Issues	104,651										122,356
Issuance or Sale of Equity, Can Be Raised | $	$ 15,000,000
Stock Issued During Period, Value, New Issues | $	$ 450,000										$ 319,196
Sale of Stock, Remaining Available Balance | $											$ 14,680,805

Note 5 - Stockholders' Equity_4

Note 5 - Stockholders' Equity, Stock Options and Warrants - Valuation Assumptions (Details)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Expected dividend yield	0.00%	0.00%
Expected stock price volatility		66.00%
Expected life of options (in years) (Year)	10 years	10 years
Measurement Input, Expected Dividend Rate [Member]
Warrants and Rights Outstanding, Measurement Input	0	0
Measurement Input, Price Volatility [Member]
Warrants and Rights Outstanding, Measurement Input		59
Measurement Input, Expected Term [Member]
Warrants and Rights Outstanding, Measurement Input	5	5
Minimum [Member]
Expected stock price volatility	78.60%
Risk-free interest rate	1.50%	2.46%
Minimum [Member] | Measurement Input, Price Volatility [Member]
Warrants and Rights Outstanding, Measurement Input	78.6
Minimum [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrants and Rights Outstanding, Measurement Input	1.39	2.33
Maximum [Member]
Expected stock price volatility	82.40%
Risk-free interest rate	2.76%	3.07%
Maximum [Member] | Measurement Input, Price Volatility [Member]
Warrants and Rights Outstanding, Measurement Input	82.4
Maximum [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrants and Rights Outstanding, Measurement Input	2.58	2.96

Note 5 - Stockholders' Equity_5

Note 5 - Stockholders' Equity, Stock Options and Warrants - Summary of Transactions for Stock Options and Warrants (Details) - $ / shares	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Number of Shares Outstanding (in shares)	766,424
Warrant [Member]
Number of Shares Outstanding (in shares)	362,664	195,126
Average Exercise Price Outstanding (in dollars per share)	$ 41.67	$ 237.40
Number of Shares Issued (in shares)	1,869,299	233,615
Average Exercise Price Issued (in dollars per share)	$ 9.25	$ 10.67
Number of Shares Forfeited (in shares)	(653)	(1,071)
Average Exercise Price Forfeited (in dollars per share)	$ 3,249.28	$ 1,995.53
Number of Shares Exercised (in shares)	(59,700)	(65,006)
Average Exercise Price Exercised (in dollars per share)	$ 0.10	$ 10
Number of Shares Outstanding (in shares)	2,171,610	362,664
Average Exercise Price Outstanding (in dollars per share)	$ 15.26	$ 41.67
Share-based Payment Arrangement, Option [Member]
Number of Shares Outstanding (in shares)	366,928	276,498
Average Exercise Price Outstanding (in dollars per share)	$ 17.03	$ 19.95
Number of Shares Issued (in shares)	423,295	109,886
Average Exercise Price Issued (in dollars per share)	$ 6.53	$ 10.13
Number of Shares Forfeited (in shares)	(23,799)	(19,456)
Average Exercise Price Forfeited (in dollars per share)	$ 13.30	$ 20
Number of Shares Exercised (in shares)
Average Exercise Price Exercised (in dollars per share)
Average Exercise Price Exercised (in dollars per share)
Number of Shares Outstanding (in shares)	766,424	366,928
Average Exercise Price Outstanding (in dollars per share)	$ 11.34	$ 17.03

Note 5 - Stockholders' Equity_6

Note 5 - Stockholders' Equity, Stock Options and Warrants - Summary of Status of Options and Warrants Outstanding (Details)	12 Months Ended
	Dec. 31, 2019$ / sharesshares
Shares, options (in shares) | shares	766,424
Shares, warrants (in shares) | shares	2,171,610
Minimum [Member]
Warrant exercises, exercise price per share (in dollars per share)	$ 2.50
Maximum [Member]
Warrant exercises, exercise price per share (in dollars per share)	$ 3,095
Warrant One [Member]
Shares, warrants (in shares) | shares	250,145
Weighted average remaining life, warrants (Year)	4 years 204 days
Warrant One [Member] | Minimum [Member]
Warrant exercises, exercise price per share (in dollars per share)	$ 0.10
Warrant One [Member] | Maximum [Member]
Warrant exercises, exercise price per share (in dollars per share)	8.36
Warrant Two [Member]
Warrant exercises, exercise price per share (in dollars per share)	$ 10
Shares, warrants (in shares) | shares	1,674,088
Weighted average remaining life, warrants (Year)	4 years 80 days
Warrant Three [Member]
Shares, warrants (in shares) | shares	237,970
Weighted average remaining life, warrants (Year)	3 years 83 days
Warrant Three [Member] | Minimum [Member]
Warrant exercises, exercise price per share (in dollars per share)	$ 10.71
Warrant Three [Member] | Maximum [Member]
Warrant exercises, exercise price per share (in dollars per share)	22.50
Warrant Four [Member]
Warrant exercises, exercise price per share (in dollars per share)	$ 1,237.50
Shares, warrants (in shares) | shares	9,407
Weighted average remaining life, warrants (Year)	244 days
Stock Options One [Member]
Options, lower limit (in dollars per share)	$ 2.61
Options, upper limit (in dollars per share)	$ 6.50
Shares, options (in shares) | shares	157,848
Weighted average remaining life, options (Year)	9 years 193 days
Stock Options Two [Member]
Options, lower limit (in dollars per share)	$ 7.324
Options, upper limit (in dollars per share)	$ 8.491
Shares, options (in shares) | shares	285,826
Weighted average remaining life, options (Year)	9 years 25 days
Stock Options Three [Member]
Options, lower limit (in dollars per share)	$ 9
Options, upper limit (in dollars per share)	$ 14.70
Shares, options (in shares) | shares	310,882
Weighted average remaining life, options (Year)	7 years 182 days
Stock Options Four [Member]
Options, lower limit (in dollars per share)	$ 21
Options, upper limit (in dollars per share)	$ 51.25
Shares, options (in shares) | shares	11,045
Weighted average remaining life, options (Year)	6 years 328 days
Stock Options Five [Member]
Options, lower limit (in dollars per share)	$ 657.50
Options, upper limit (in dollars per share)	$ 5,962.50
Shares, options (in shares) | shares	823
Weighted average remaining life, options (Year)	4 years 142 days

Note 5 - Stockholders' Equity_7

Note 5 - Stockholders' Equity, Stock Options and Warrants - Schedule of Listing of Stock Options and Warrants (Details)	Dec. 31, 2019$ / sharesshares
Shares, options (in shares) | shares	766,424
Shares, warrants (in shares) | shares	2,171,610
Minimum [Member]
Price, options (in dollars per share)	$ 0.45
Warrant exercises, exercise price per share (in dollars per share)	2.50
Maximum [Member]
Price, options (in dollars per share)	5,962.50
Warrant exercises, exercise price per share (in dollars per share)	$ 3,095
Warrants 2015 [Member]
Shares, warrants (in shares) | shares	9,407
Warrant exercises, exercise price per share (in dollars per share)	$ 1,237.50
Warrants 2016 [Member]
Shares, warrants (in shares) | shares	25,233
Warrant exercises, exercise price per share (in dollars per share)	$ 10
Warrants 2017 [Member]
Shares, warrants (in shares) | shares	108,295
Warrants 2017 [Member] | Minimum [Member]
Warrant exercises, exercise price per share (in dollars per share)	$ 10.71
Warrants 2017 [Member] | Maximum [Member]
Warrant exercises, exercise price per share (in dollars per share)	$ 22.50
Warrants 2018 [Member]
Shares, warrants (in shares) | shares	219,076
Warrants 2018 [Member] | Minimum [Member]
Warrant exercises, exercise price per share (in dollars per share)	$ 8.36
Warrants 2018 [Member] | Maximum [Member]
Warrant exercises, exercise price per share (in dollars per share)	13.125
Warrants 2019 [Member]
Warrant exercises, exercise price per share (in dollars per share)	1,809,599
Warrants 2019 [Member] | Minimum [Member]
Warrant exercises, exercise price per share (in dollars per share)	2.50
Warrants 2019 [Member] | Maximum [Member]
Warrant exercises, exercise price per share (in dollars per share)	$ 11.88
Stock Options 2011 [Member]
Shares, options (in shares) | shares	17
Price, options (in dollars per share)	$ 2,812.50
Stock Options 2012 [Member]
Shares, options (in shares) | shares	171
Stock Options 2012 [Member] | Minimum [Member]
Price, options (in dollars per share)	$ 1,312.50
Stock Options 2012 [Member] | Maximum [Member]
Price, options (in dollars per share)	$ 1,500
Stock Options 2013 [Member]
Shares, options (in shares) | shares	150
Stock Options 2013 [Member] | Minimum [Member]
Price, options (in dollars per share)	$ 1,481.25
Stock Options 2013 [Member] | Maximum [Member]
Price, options (in dollars per share)	$ 5,962.50
Stock Options 2014 [Member]
Shares, options (in shares) | shares	84
Stock Options 2014 [Member] | Minimum [Member]
Price, options (in dollars per share)	$ 1,625
Stock Options 2014 [Member] | Maximum [Member]
Price, options (in dollars per share)	$ 4,312.50
Stock Options 2015 [Member]
Shares, options (in shares) | shares	401
Stock Options 2015 [Member] | Minimum [Member]
Price, options (in dollars per share)	$ 657.50
Stock Options 2015 [Member] | Maximum [Member]
Price, options (in dollars per share)	$ 862.50
Stock Options 2016 [Member]
Shares, options (in shares) | shares	9,617
Stock Options 2016 [Member] | Minimum [Member]
Price, options (in dollars per share)	$ 22.50
Stock Options 2016 [Member] | Maximum [Member]
Price, options (in dollars per share)	$ 51.25
Stock Options 2017 [Member]
Shares, options (in shares) | shares	235,053
Stock Options 2017 [Member] | Minimum [Member]
Price, options (in dollars per share)	$ 10.10
Stock Options 2017 [Member] | Maximum [Member]
Price, options (in dollars per share)	$ 21
Stock Options 2018 [Member]
Shares, options (in shares) | shares	97,636
Stock Options 2018 [Member] | Minimum [Member]
Price, options (in dollars per share)	$ 6.19
Stock Options 2018 [Member] | Maximum [Member]
Price, options (in dollars per share)	$ 13.50
Stock Options 2019 [Member]
Shares, options (in shares) | shares	423,295
Stock Options 2019 [Member] | Minimum [Member]
Price, options (in dollars per share)	$ 2.61
Stock Options 2019 [Member] | Maximum [Member]
Price, options (in dollars per share)	$ 9

Note 6 - Notes Receivable (Deta

Note 6 - Notes Receivable (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Mar. 31, 2018
Advances to De Lage Landen [Member]
Payments to Acquire Notes Receivable		$ 997,500
CytoBioscience [Member] | Promissory Notes Receivable [Member]
Financing Receivable, after Allowance for Credit Loss, Total	$ 1,112,524
Notes Receivable, Interest Rate, Stated Percentage	8.00%
Helomics Holding Corp. [Member]
Financing Receivable, after Allowance for Credit Loss, Total	$ 2,140,013	1,165,013
Share Exchange Agreement, Outstanding Receivables, Amount Converted		$ 500,000
Share Exchange Agreement, Shares Received Upon Conversion of Receivables		833,333
Share Exchange Agreement, Convertible Notes, Percent of Stock		5.00%	5.00%
Investment, Ownership Percent		25.00%
Payments to Acquire Notes Receivable	975,000
Interest Receivable	70,369	$ 29,215
Reduction to Loan due to Cumulative Equity Method Investment Losses Incurred	$ 1,190,967

Note 7 - Notes Payable (Details

Note 7 - Notes Payable (Details Textual)	Sep. 27, 2019	Sep. 28, 2018USD ($)$ / sharesshares	Oct. 31, 2019USD ($)	Sep. 30, 2019USD ($)$ / sharesshares	Feb. 27, 2019USD ($)shares	Apr. 06, 2020USD ($)	Dec. 31, 2019USD ($)shares	Jul. 15, 2019USD ($)$ / sharesshares	Dec. 31, 2019USD ($)shares	Dec. 31, 2018USD ($)	Dec. 31, 2017USD ($)	Dec. 31, 2020	May 21, 2019shares
Debt Instrument, Face Amount							$ 5,146,226		$ 5,146,226	$ 2,667,727
Payments for Penalties									202,294
Bridge Loan							4,795,800		4,795,800	1,634,914
Debt Instrument, Unamortized Discount, Total							350,426		350,426	1,032,813
Short-term Debt, Total							4,795,800		4,795,800	1,634,914
Gain (Loss) on Extinguishment of Debt, Total									(581,073)
Debt Discount Recognized for extension of Notes Payable.									$ 162,750
Stock Issued During Period, Shares, Extension of Notes Payable | shares									30,000
Derivative Liability, Total							50,989		$ 50,989	272,745
Dr. Schwartz Notes Warrants [Member]
Derivative Liability, Total							$ 0		0	22,644
Other Expense [Member]
Embedded Derivative, Gain (Loss) on Embedded Derivative, Net, Total									221,756	372,263	$ 50,989
Extension of Notes Payable [Member]
Gain (Loss) on Extinguishment of Debt, Total									581,073
Chief Executive Officer [Member]
Proceeds from Related Party Debt								$ 1,920,000		370,000
Converison of Bridge Loan to Common Stock [Member]
Debt Conversion, Original Debt, Amount									$ 378,573
Debt Conversion, Converted Instrument, Shares Issued | shares									103,415
Bridge Loan Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares		107,178
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares		$ 11.55
Dr. Schwartz Notes Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares								22,129
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares								$ 8.36
Warrant for Promissory Notes [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares				68,237
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares				$ 6.21
Warrants Issued for Extension of Notes Payable [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares							13,000		13,000
Warrants Issued for 2019 Agreement [Member] | Chief Executive Officer [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares													5,753
Convertible Promissory Note [Member]
Debt Instrument, Face Amount							$ 1,989,104		$ 1,989,104	2,297,727
Dr. Schwartz Note, One [Member]
Debt Instrument, Face Amount										370,000
Debt Instrument, Unamortized Discount, Total										63,028
DrSchwartz Notes [Member]
Debt Instrument, Face Amount							$ 2,115,000		$ 2,115,000
Debt Instrument, Interest Rate, Stated Percentage							8.00%		8.00%
DrSchwartz Notes [Member] | Forecast [Member]
Debt Instrument, Interest Rate, Stated Percentage												12.00%
Promissory Note [Member]
Debt Instrument, Face Amount							$ 680,833		$ 680,833
Promissory Note [Member] | Forecast [Member]
Proceeds from Short-term Debt, Total						$ 1,200,000
Borrowings Against Equity Line [Member]
Debt Instrument, Face Amount							$ 440,000		$ 440,000
Debt Instrument, Interest Rate, Stated Percentage							8.00%		8.00%
Payments for Penalties									$ 6,367
Penalties Accrued							$ 35,468		35,468
Proceeds from Short-term Debt, Total									478,159
Repayments of Short-term Debt, Total									118,527
Short-term Debt, Total							361,289		361,289
Bridge Notes [Member] | Convertible Promissory Note [Member]
Debt Instrument, Face Amount		$ 2,297,727
Proceeds from Notes Payable, Total		$ 2,000,000
Stock Issued During Period, Shares, New Issues | shares		65,000			16,667
Debt Instrument, Interest Rate, Stated Percentage		8.00%
Debt Instrument, Increase (Decrease), Net, Total					$ 344,659
Payments for Penalties							144,378
Penalties Accrued							497,276		497,276
Bridge Loan							1,989,104		1,989,104
Debt Instrument, Unamortized Discount, Total							133,839		$ 133,839
Debt Instrument, Convertible, Threshold Trading Days									20
Conversion Shares, Sum of Number of Conversion Shares Plus Inducement Shares | shares									267,833
Notes Assumed from Acquisiton [Member]
Repayments of Long-term Debt, Total			$ 303,333
Payment for Debt Extinguishment or Debt Prepayment Cost			$ 18,216
Securities Purchase Agreements [Member] | Promissory Note [Member]
Debt Instrument, Face Amount				$ 847,500
Stock Issued During Period, Shares, New Issues | shares				8,857
Debt Instrument, Interest Rate, Stated Percentage				8.00%
Payments for Penalties									$ 33,333
Penalties Accrued							136,167		136,167
Debt Instrument, Unamortized Discount, Total							216,587		216,587
Debt Instrument, Convertible, Threshold Trading Days	20
Proceeds from Short-term Debt, Total				$ 700,000
Repayments of Short-term Debt, Total									166,667
Short-term Debt, Total							$ 680,833		$ 680,833

Note 7 - Notes Payable - Notes

Note 7 - Notes Payable - Notes Payable (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Notes Payable, Gross	$ 5,146,226	$ 2,667,727
Debt Instrument, Unamortized Discount, Total	350,426	1,032,813
Notes Payable	4,795,800	1,634,914
Convertible Promissory Note [Member]
Notes Payable, Gross	1,989,104	2,297,727
Promissory Note [Member]
Notes Payable, Gross	680,833
Borrowings Against Equity Line, One [Member]
Notes Payable, Gross	18,563
Borrowings Against Equity Line, Two [Member]
Notes Payable, Gross	147,783
Borrowings Against Equity Line, Three [Member]
Notes Payable, Gross	194,943
Dr. Schwartz Note, Two [Member]
Notes Payable, Gross	$ 2,115,000	$ 370,000

Note 7 - Notes Payable - Change

Note 7 - Notes Payable - Change in Fair Value of Derivative Liabilities (Details) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Derivative liability balance at December 31, 2017	$ 272,745
Derivative instruments recognized	69,722	645,008
Gain recognized to revalue derivative instrument at fair value	(221,756)	(372,263)
Adjustments to derivative liability for warrants issued	(47,078)
Reduction of derivative liability	(22,644)
Derivative liability balance at December 31, 2018	$ 50,989	$ 272,745

Note 8 - Loss Per Share - Share

Note 8 - Loss Per Share - Shares Used in Basic and Diluted Loss Per Common Share Computations (Details) - USD ($)		12 Months Ended
		Dec. 31, 2019	Dec. 31, 2018
Net loss attributable to common shareholders per common share: basic and diluted calculation		$ (19,680,701)	$ (10,086,477)
Weighted average common shares outstanding-basic (in shares)		2,870,132	1,281,629
Effect of diluted stock options, warrants and preferred stock (1) (in shares)	[1]
Weighted average common shares outstanding-diluted (in shares)		2,870,132	1,281,629
Loss per common share-basic and diluted (in dollars per share)		$ (6.86)	$ (7.87)
[1]	(1) The following is a summary of the number of underlying shares outstanding at the end of the respective periods that have been excluded from the diluted calculations because the effect on loss per common share would have been anti-dilutive: Year Ended December 31, 2019 2018 Options 766,424 366,928 Warrants 2,171,610 362,664 Convertible debt 82,751 329,409 Preferred stock: series B 7,925 7,925 Preferred stock: series D 350,000 - Preferred stock: series E 594,383 -

Note 8 - Loss Per Share - Antid

Note 8 - Loss Per Share - Antidilutive Securities Excluded from the Diluted Calculations (Details) - shares	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Share-based Payment Arrangement, Option [Member]
Antidilutive Securities (in shares)	766,424	366,928
Warrant [Member]
Antidilutive Securities (in shares)	2,171,610	362,664
Convertible Debt Securities [Member]
Antidilutive Securities (in shares)	82,751	329,409
Series B Convertible Preferred Stock [Member]
Antidilutive Securities (in shares)	7,925	7,925
Series D Convertible Preferred Stock [Member]
Antidilutive Securities (in shares)	350,000
Series E Convertible Preferred Stock [Member]
Antidilutive Securities (in shares)	594,383

Note 9 - Income Taxes (Details

Note 9 - Income Taxes (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent		21.00%	34.00%
Income Tax Expense (Benefit), Continuing Operations, Adjustment of Deferred Tax (Asset) Liability			$ 0
Valuation Allowance Percentage	100.00%		100.00%
Federal Income Tax Expense (Benefit), Continuing Operations, Total	$ 0
Unrecognized Tax Benefits, Ending Balance	0
Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued, Total	0	$ 0
Domestic Tax Authority [Member]
Operating Loss Carryforwards, Total	291,476,788	40,444,754
Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration	264,379,011	34,529,255
Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration	27,097,777	5,915,499
Operating Loss Carryforwards, Valuation Allowance, Total	58,991,353	9,603,237
State and Local Jurisdiction [Member]
Operating Loss Carryforwards, Total	213,762,905	13,114,182
Operating Loss Carryforwards, Valuation Allowance, Total	21,414,302	1,416,758
Foreign Tax Authority [Member]
Operating Loss Carryforwards, Total	773,455	421,782
Operating Loss Carryforwards, Valuation Allowance, Total	$ 236,746	$ 132,722

Note 9 - Income Taxes - Reconci

Note 9 - Income Taxes - Reconciliation of Income Tax Benefit (Expense) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Statutory federal income tax benefit	$ 3,977,561	$ 2,118,160
State tax benefit, net of federal taxes	368,635	66,117
Foreign tax benefit	104,050	132,931
Foreign operations tax rate differential	(73,869)	(94,373)
State rate adjustment	(17,585)	15,355
R&D tax credit	51,143	22,532
Nondeductible/nontaxable items	(517,465)	(118,905)
State NOL adjustment	(1,054,778)	746,479
OID and derivatives	141,908	(159,037)
Helomics purchase adjustment	66,394,188
Other	115,896	47,868
Valuation allowance increase	(69,489,684)	(2,777,127)
Total income tax benefit	$ 0

Note 9 - Income Taxes - Compone

Note 9 - Income Taxes - Components of Deferred Income Taxes (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Depreciation		$ 4,488
Inventory	6,891	6,991
Compensation accruals	56,670	60,905
Accruals and reserves		77,777
Charitable contribution carryover	3,740	3,972
Derivatives	10,708	57,276
Related party investments	657,633	481,652
Intangibles	295,941	2,020
NSQO compensation	1,589,430	1,019,139
NOL and credits	78,417,618	9,655,388
Total deferred tax assets	81,046,111	11,369,608
Original issue discount	(14,021)	(216,891)
Total deferred tax liabilities	(403,710)	(216,891)
Net deferred tax assets	80,642,401	11,152,717
Less: valuation allowance	(80,642,401)	(11,152,717)
Total

Note 10 - Leases (Details Textu

Note 10 - Leases (Details Textual)	12 Months Ended
	Dec. 31, 2019USD ($)ft²	Dec. 31, 2018USD ($)
Operating Lease, Expense | $	$ 431,170	$ 69,013
Corporate Office, Minnesota [Member]
Lessee, Operating Lease, Term of Contract	3 years
Area of Real Estate Property	5,773
Corporate Office, Minnesota [Member] | Office Space [Member]
Area of Real Estate Property	2,945
Corporate Office, Minnesota [Member] | Manufacturing Facility [Member]
Area of Real Estate Property	2,828
Skyline Medical Europe’s Offices Lease [Member]
Area of Real Estate Property	2,000
Skyline Medical Europe’s Offices Lease [Member] | Office Space [Member]
Area of Real Estate Property	1,250
Skyline Medical Europe’s Offices Lease [Member] | Storage Space [Member]
Area of Real Estate Property	750
Helomics' Offices [Member]
Lessee, Operating Lease, Term of Contract	3 years
Area of Real Estate Property	17,417
Helomics' Offices [Member] | Office Space [Member]
Area of Real Estate Property	1,000
Helomics' Offices [Member] | Laboratory [Member]
Area of Real Estate Property	16,417

Note 10 - Leases - Lease Inform

Note 10 - Leases - Lease Information (Details)	Dec. 31, 2019
Weighted average remaining lease term – operating leases in years (Year)	3 years 102 days
Weighted average discount rate – operating leases	8.00%

Note 10 - Leases - Rent Obligat

Note 10 - Leases - Rent Obligation (Details)	Dec. 31, 2019USD ($)
2020	$ 476,468
2021	111,353
2022	43,154
2023	44,017
2024	44,897
2025 and thereafter	112,271
Total lease payments	832,160
Less interest	102,415
Present value of lease liabilities	$ 729,745

Note 11 - Related Party Trans_2

Note 11 - Related Party Transactions (Details Textual) - USD ($)	May 01, 2019	Apr. 01, 2019
Director [Member]
Related Party Transaction, Monthly Cash Payment	$ 13,500	$ 12,000

Note 12 - Retirement Savings _2

Note 12 - Retirement Savings Plans (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Defined Contribution Plan, Employer Matching Contribution, Percent of Match	100.00%	100.00%
Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent	4.00%	4.00%
Defined Contribution Plan, Employer Contribution Amount	$ 110,714	$ 51,647
Defined Contribution Plan, Employer Discretionary Contribution Amount	$ 0	$ 0

Note 13 - Subsequent Events (De

Note 13 - Subsequent Events (Details Textual) - USD ($)

Mar. 19, 2020

Mar. 15, 2020

Mar. 05, 2020

Mar. 04, 2020

Mar. 02, 2020

Jul. 10, 2018

Feb. 29, 2020

Jan. 31, 2020

Apr. 06, 2020

Mar. 27, 2020

Dec. 31, 2019

Dec. 31, 2018

Mar. 07, 2020

Feb. 05, 2020

Stock Issued During Period, Value, Inducement to Equity Line

$ 450,000

Debt Instrument, Face Amount

5,146,226

$ 2,667,727

Debt Conversion, Converted Instrument, Amount

378,573

Gain (Loss) on Extinguishment of Debt, Total

$ (581,073)

Stock Issued During Period, Shares, Issued for Services

25,000

Stock Issued During Period, Shares, Extension of Notes Payable

30,000

CEO Promissory Note Exchange Agreement [Member]

Gain (Loss) on Extinguishment of Debt, Total

$ 310,000

Notes Payable [Member]

Debt Instrument, Increase for Extension

$ 300,000

Promissory Note [Member]

Debt Instrument, Face Amount

$ 680,833

Promissory Note [Member] | Forecast [Member]

Proceeds from Short-term Debt, Total

$ 1,200,000

Subsequent Event [Member]

Stock Issued During Period, Shares, Inducement to Equity Line

943,000

Stock Issued During Period, Value, Inducement to Equity Line

$ 1,869,899

Stock Issued During Period, Shares, Extension of Notes Payable

30,000

Subsequent Event [Member] | Private Placement [Member]

Stock Issued During Period, Shares, New Issues

260,000

Sale of Stock, Price Per Share

$ 2.12

Proceeds from Issuance or Sale of Equity, Total

$ 3,498,612

Proceeds from Issuance or Sale of Equity, Net of Stock Issuance Costs

$ 3,127,112

Subsequent Event [Member] | Chief Executive Officer [Member]

Debt Conversion, Converted Instrument, Shares Issued

50,000

Subsequent Event [Member] | Chief Executive Officer [Member] | Promissory Note Exchange Agreement [Member]

Debt Conversion, Converted Instrument, Amount

$ 2,115,000

Subsequent Event [Member] | Investor of Promissory Note [Member]

Stock Issued During Period, Shares, New Issues

46,875

Subsequent Event [Member] | InventaBio Tech and its subsidiary Soluble [Member]

Stock Issued During Period, Shares, Purchase of Assets

125,000

Subsequent Event [Member] | Vendor [Member]

Stock Issued During Period, Shares, Issued for Services

150,000

Subsequent Event [Member] | Warrants Issued With Promissory Note, One [Member]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

94,631

Subsequent Event [Member] | Warrants Issued With Promissory Note, Two [Member]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

92,700

Subsequent Event [Member] | Warrants Issued With Promissory Note [Member]

Class of Warrant or Right, Exercise Price of Warrants or Rights

$ 2.992

Subsequent Event [Member] | Warrants issued with Private Placement, One [Member]

Class of Warrant or Right, Number of Securities Called by Each Warrant or Right

1

Warrants and Rights Outstanding, Term

5 years 182 days

Subsequent Event [Member] | Warrants issued with Private Placement, Two [Member]

Class of Warrant or Right, Exercise Price of Warrants or Rights

$ 1.88

Class of Warrant or Right, Number of Securities Called by Each Warrant or Right

1

Warrants and Rights Outstanding, Term

2 years

Subsequent Event [Member] | Prefunded Warrant [Member]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

1,390,166

Class of Warrant or Right, Exercise Price of Warrants or Rights

$ 0.0001

Price of Warrant

$ 2.12

Subsequent Event [Member] | Loans Payable [Member]

Debt Instrument, Face Amount

1,098,684

Proceeds from Short-term Debt, Total

1,020,000

Repayments of Short-term Debt, Total

$ 657,105

Subsequent Event [Member] | Promissory Note [Member]

Debt Instrument, Face Amount

$ 1,450,000

Debt Instrument, Interest Rate, Stated Percentage

8.00%

Subsequent Event [Member] | Promissory Note [Member] | Chief Executive Officer [Member]

Debt Instrument, Interest Rate, Stated Percentage

12.00%

Subsequent Event [Member] | Promissory Note [Member] | Promissory Note, One [Member]

Debt Instrument, Face Amount

$ 490,000

Proceeds from Short-term Debt, Total

$ 400,000

Subsequent Event [Member] | Promissory Note [Member] | Promissory Note, Two [Member]

Debt Instrument, Face Amount

$ 480,000

$ 480,000

Proceeds from Short-term Debt, Total

$ 400,000